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Abstract
HYPOTHESIS AND SPECIFIC AIMS OF STUDY: The primary aim of this study is to
evaluate the hypothesis that increasing cumulative organ dysfunction in patients presenting to
the Emergency Department (ED) with severe sepsis or septic shock correlates with 28‐day and
total in‐hospital mortality, mechanical ventilation requirement and vasopressor use within 72
hours of presentation. This investigation also aims to elucidate differences in patients with high
cumulative organ dysfunction scores (≥5) and low cumulative organ dysfunction scores (<5), as
well as externally validate the Mortality in Emergency Department Sepsis (MEDS) score.
METHODS: This study is a retrospective chart review of patients at Yale – New Haven
Hospital who presented to the ED with severe sepsis or septic shock. Included patients were at
least 18 years of age, met at least two of four criteria for Systemic Inflammatory Response
Syndrome (SIRS), had a documented suspicion of clinical infection, as well as manifested acute
organ injury. Patients were stratified according to the number of cumulative organ failures. The
principle outcome measure in this study was in‐hospital mortality. Secondary outcomes include
vasopressor use within 72 hours and mechanical ventilation rates, as well as MEDS scores.
RESULTS: Of the 521 patients who met criteria for enrollment in our study, 83.5%
(n=435) were classified as severe sepsis patients and 16.5% (n=86) as septic shock patients. The
overall in‐hospital mortality rate in this study was 15.2% (n=79). Septic shock patients
experienced higher mortality (33.7%, n=29) than patients diagnosed with severe sepsis (11.5%,
n=50).
The five or more organ injury group had more males (59.5%) than females (40.5%), likely
due to a higher number of baseline co‐morbidities among males in that group, more liver
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disease and congestive heart failure and had fewer residents presenting from extended care
facilities.
Organ failure groups had mortality rates as follows: one or two organ failures, 8.7%;
three or four, 13.8%; five or six, 19.5%; and seven or more, 55.9% (p<0.05 when comparing the
one or two organ dysfunction group to the highest two groups (five or six and seven or more
organ dysfunctions). Fifty‐four patients (48.6%) in the higher cumulative organ failures group
were mechanically ventilated compared to 99 (24.1%) in the fewer cumulative organ failures
group (p<0.0001). Nearly 56% (n=56) in the higher dysfunctional group versus 17% (n=70) in the
lower dysfunctional group received vasopressor support within 72 hours (p<0.0001).
Patients with fewer than five organ failures had a mean MEDS score of 10.7 ± 4.5, as
compared to the other group with mean MEDS score of 12.5 ± 4.9 (p=0.0002). When the
experimental groups are further stratified, the MEDS scores neither trended with cumulative
organ failure, nor with the three study end‐points, including mortality, vasopressor and
mechanical ventilation rates.
CONCLUSION: This study demonstrated that the Emergency Department assessment of
cumulative organ dysfunction is a promising measurement of disease severity in patients who
present with severe sepsis and septic shock because it correlates with in‐hospital mortality,
early vasopressor and mechanical ventilation rates. The MEDS scoring system was not
externally validated by this study.
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Introduction
The following literature review will explore several key clinical and physiological aspects
of severe sepsis in order to emphasize the relevance of this critical illness as it pertains to
emergency physicians today. First, the epidemiologic impact of severe sepsis on patients and
the health care system at large is explored. Next, we highlight key definitions used to
standardized clinical diagnoses of sepsis and research inclusion criteria. A brief discussion of the
pathophysiology of sepsis syndrome is included to provide background for current diagnostic
criteria, monitoring protocols and treatment standards.
Given that early identification has proven chiefly important in reducing sepsis‐related
mortality, a synopsis of the clinical and laboratory data recommended for diagnosis, predictors
of mortality and markers of illness severity, such as organ dysfunction, is presented as
fundamental criteria on which the risk stratification of patients with severe sepsis is based.
Similarly, the strengths and limitations of global scoring systems for mortality risk assessment
frequently applied to septic populations are included, given that they integrate knowledge
about critical illness into a clinically predictive tool for mortality.
Finally, current treatment recommendations are emphasized as the mechanisms by
which mortality is ultimately reduced. Presentation of all of these elements of sepsis syndrome
provide an necessary context within which to understand the motivation for this research,
import of the clinical question addressed, rationale for the parameters evaluated and data
collected and current clinical limitations in improving survival among patients with severe sepsis
and septic shock.
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Epidemiology
According to a recent National Vital Statistics Report based on 2006 data from the
National Center for Health Statistics, septicemia is the 10th leading cause of death in the United
States (1), affecting 750,000 hospitalized patients and resulting in 215,000 deaths each year (2).
It is estimated that approximately two‐thirds, or 571,000, of these patients present to the
Emergency Department (ED) annually, a potential underestimate given that this figure does not
include patients in whom the illness is detected later in the hospitalization (2, 3).
Records from 2006 also demonstrate that sepsis is the 6th most expensive disease
managed by hospitals in this country, with costs reaching $30.3 billion or 3.2% of the total
healthcare bill, up from $24.8 billion or 2.8% the previous year. Furthermore, sepsis ranks 3rd
most expensive disease for Medicare and Medicaid payers (4, 5). National costs will likely rise in
the setting of a growing elderly population susceptible to sepsis. For example, individual patient
costs rose $8,800 largely due to increased ICU length of stays after an integrated sepsis protocol
was instituted at Beth Israel Deaconess Medical Center (6). At the same time, life expectancy
and quality‐adjusted life years were higher, making interventions cost‐effective despite
increasing expenditure.
Demographically, patients with sepsis are more like to be elderly (3, 7, 8). A 2003 study
of national epidemiological data spanning from 1979 through 2000 noted that the mean age of
patients during that period increased from 57.4 to 60.8 years (7). However, sepsis tended to
develop later in life for women (mean age 62.1 years) than men (mean age 56.9 years).
Although men accounted for 48% of the patients with sepsis, they were more likely to have
sepsis than women when adjusted for sex in the population. A later review of the National
Hospital Ambulatory Medical Care Survey (NHAMCS) from 2001‐2004 observed that the gender
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distribution had shifted to 54% of patients suspected of having severe sepsis being female.
Finally, approximately 17% of all patients reside in nursing homes (3).
Nguyen and others compiled data regarding community‐ and hospital‐acquired
infections from 16 studies conducted between 1963 and 1998 to conclude that the distribution
of the sites of infection in patients with severe sepsis and septic shock are pulmonary (35%),
intra‐abdominal (21%), genitourinary (13%), skin and soft tissue (7%) and other (8%) (9). More
recent data show a slightly different distribution with pneumonia suspected in 32‐45% of cases,
urinary system in 27‐28%, skin and soft tissue in 9‐20%, abdomen in 1‐18% and blood or central
line sources in 3‐6% (10‐12). In patients over 65 years of age, urinary sources are the most
common site (13). Furthermore, gram positive bacteria are the predominant pathogens causing
severe sepsis and septic shock, accounting for 52.1% compared to 37.6% for gram‐negative
bacteria, 4.7% polymicrobial infections, 1.0% anaerobes and 4.6% fungi (7).
Regarding mortality in sepsis, Shapiro and colleagues found in a prospective
investigation that 28‐day in‐hospital mortality for sepsis syndrome prior to the implementation
of early goal‐directed therapy (EGDT) was 4.1% overall, while 1‐year mortality was 22% (14).
When stratified according to illness severity, in‐hospital mortality rates for sepsis were 1.3%,
severe sepsis 9.2% and septic shock 28%. Other estimates of mortality derived from data from
eight countries approximate that mortality could be as high as 53.6% in patients with hospital‐
acquired infections prior to the implementation invasive protocolized hemodynamic
optimization therapies (15). A potentially critical factor in rising mortality rates is that the
proportion of patients with severe sepsis or septic shock who have any organ failure has
increased over time for unclear reasons, from 19.1% in the early 1980s to 33.6% at the turn of
the century.
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Given these dynamics, early detection and management of sepsis in the Emergency
Department is critically linked to outcomes. Despite existing advancements in management,
further reduction in mortality is needed. A necessary area of future research addresses ED risk
stratification of patients presenting with sepsis syndrome, which will enhance early
identification of septic patients, enable early therapeutic interventions and allow for
appropriate and timely disposition from crowded Emergency Departments. Each of these areas
is of vital concern in the movement to improve sepsis outcomes as promulgated by the Surviving
Sepsis Campaign (16, 17) and endorsed by numerous medical societies and quality improvement
initiatives.

Definitions
In a 1992 statement of a consensus conference from the American College of Chest
Physicians (ACCP) and the Society of Critical Care Medicine (SCCM), Bone et al. first familiarized
the medical community with a description of the Systemic Inflammatory Response Syndrome
(SIRS) (18). SIRS is defined by two or more of the following clinical findings: (a) body
temperature >38⁰C or <36⁰C; (b) heart rate >90 min‐1; (c) respiratory rate >20 min‐1 or PaCO2
<32 mmHg; and (d) white blood cell count of >12,000 cells μL‐1 or <4,000 μL‐1 or >10% immature
neutrophils (bands). The statement also defines “sepsis” as SIRS plus infection (18). Of note,
signs of SIRS do occur in the absence of infection, such as with burns, pancreatitis and trauma
(19, 20).
Increasing in severity, “severe sepsis” is classified as sepsis plus organ dysfunction,
hypoperfusion or hypotension, while “septic shock” is described as sepsis with hypotension
refractory to adequate fluid resuscitation (18) or a state of acute circulatory failure (21).
Therefore, by definition, septic shock is the most perilous subset of severe sepsis (20). Finally,
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“hypotension” is defined by systolic blood pressure below 90 mmHg, a mean arterial pressure
(MAP) <60 or a reduction in systolic blood pressure greater than 40 mmHg from baseline (19).
Definitions of severe sepsis and septic shock include a component in the progression of
the illness known as multiple organ dysfunction. Reports of multiple organ failure, as it was
then called, first emerged in 1969 (22). Later, a conceptual framework was introduced in 1992
by the ACCP/SCCM Consensus Conference Committee, which defined Multiple Organ
Dysfunction Syndrome (MODS) as “the presence of altered organ function in an acutely ill
patient such that homeostasis cannot be maintained without intervention” (18). It results
directly from injury (primary MODS) or from the host’s response to injury (secondary MODS).
Furthermore, MODS represents a continuum of inter‐related dysfunctions in organs that could
be either reversible or irreversible. Therefore, evaluation of organ function over time is viewed
as an essential element in prognostication. (18).
These definitions were reinforced at the International Sepsis Definitions Conference in
2001 (19). Despite efforts to bridge the gap in clinical understanding by refining definitions of
sepsis syndrome further, participants in the conference determined that there was not sufficient
evidence to support the use of biomarkers in diagnosing sepsis at that time. Additionally, the
cohort concluded that despite the usefulness of the SIRS concept, it is still too nonspecific, thus
elucidating the need for continued review and potential for future revisions of the current
definitions. Despite ongoing debate concerning SIRS, numerous clinical trials evaluating
treatments for sepsis syndrome have utilized them as enrollment criteria (23‐26). Finally,
conference participants highlighted the limitation of current definitions in staging or
prognosticating the patient’s response to the disease, thus supporting our research interest,
specifically risk stratification of septic patients, as an area where further investigation and
developments are needed (19).
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Pathophysiology
The host’s response to infection is a delicate balance between pro‐ and anti‐
inflammatory components of the immune system, as well as apoptotic mediators (27).
Proinflammatory cytokines such as tumor necrosis factor and interleukins, as well as other
plasma substances, such as nitric oxide, are mobilized (9, 28, 29), while complement and the
clotting cascade are activated causing natural anticoagulation responses to be suppressed (30).
The vascular endothelium is the primary site of these various interactions, leading to
microvascular injury, thrombosis and capillary leak which cause tissue ischemia. Diffuse
endothelial damage is the common pathway of the various classifications of organ dysfunction
from global tissue hypoxia that characterize severe sepsis and septic shock (9) (see Figure 1).
Global tissue hypoxia occurs when oxygen delivery cannot meet elemental oxygen
requirements, a relationship that is quantified by mixed venous oxygen saturation (SvO2) or
central venous oxygen saturation (ScvO2), which are considered physiologic equivalents (9, 27).
Critical determinants of ScvO2 are cardiac output (CO), oxygen consumption (VO2), hemoglobin
concentration (Hgb) and arterial oxygen saturation (SaO2). Thus, changes in ScvO2 are directly
proportional to CO, Hgb, and SaO2, while inversely proportional to VO2 (i.e. ScvO2 = (CO / Vo2) x
Hgb x SaO2). In sepsis syndrome, oxygen extraction by tissue increases as cardiac output is
decreased, by falling preload for example, causing ScvO2 to diminish. This mismatch in oxygen
delivery and consumption represents an important transition from sepsis to severe sepsis (27).
While the treatment goals of early interventions and evaluation of the clinical
progression of disease include indices of macrocirculatory perfusion such as cardiac filling
pressure, mean arterial pressure, cardiac output or mixed/central venous oxygen saturation, all
of which have been independently associated with mortality (31, 32), studies have shown that
the chief regulators of oxygen delivery in the effort to meet cellular demand are the <100 μm in
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diameter network of blood vessels that make up the microcirculation (33). Vasoactive
mediators of sepsis exert their vasodilatory effects at the arterioles causing low systemic
vascular resistance leading to hypotension, while at the level of the capillaries, endothelial
damage and persistent capillary leakage also manifests clinically as hypotension (34).

Figure 1. Pathogenic mechanisms from infection to septic shock.
The initial response to an infecting organism is a systemic response, with release of inflammatory
mediators and activation of the coagulation cascade. Microvascular injury, thrombosis, and diffuse
endothelial disruption follow, resulting in imbalance between oxygen delivery and oxygen consumption.
Global tissue hypoxia and cytopathic (cellular) hypoxia develop, leading to multiple organ dysfunction and
irreversible shock.
Reprinted from Nguyen et al. 2006. Severe sepsis and septic shock: review of the literature and Emergency
Department management guidelines (9).

Moreover, studies have determined that the severity of derangements in
microcirculatory homeostasis correlates with mortality (35‐37). In like manner, Trzeciak et al.
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demonstrates that improvements in microcirculatory flow during resuscitation reduce organ
failure at 24 hours independent of global (i.e. macrocirculatory) hemodynamics as indicated
clinically by arterial blood pressure (33). Toward this end, nitroglycerin and dobutamine have
been associated with increases in microcirculatory flow, as well as tissue perfusion and cardiac
output (38‐41) and dobutamine is currently recommended in the Early‐Goal Directed Therapy
protocol (24).

Early Identification and Risk Stratification
Because it is believed that the physiological determinants of outcomes are manifested
early in the continuum of illness in critically ill patients, medical practitioners are compelled
toward early recognition and treatment of sepsis syndrome to achieve optimal results.
However, the cryptic nature of the disease and a broad diagnostic approach contrast the timely
detection of other fatal illnesses that require early interventions such as myocardial infarction,
which have specific methods of risk stratification (i.e. ECG), leading to delays in the care of septic
patients or inappropriate treatment. Given this, the propensity toward better means of
identification and systems of risk stratification in patients with sepsis syndrome has been the
subject of recent research.

Vital Signs
Originally, easily measurable bedside parameters known as the 10 signs of vitality were
utilized for the diagnosis of sepsis syndrome. These include temperature, pulse, pain, as well
the following vital signs that could indicate a perfusion deficit: blood pressure, arterial oxygen
saturation, respiratory rate, level of consciousness, capillary refill, urinary output and
ScvO2/base deficit (42). Data show that patients whose blood pressure decreases below 80
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mmHg carry three times the risk of death when compared with patients who maintain blood
pressures greater than or equal to 80 mmHg (16% versus 5% mortality rate, respectively) (43).
While sustained hypotension indicates the transition from severe sepsis to septic shock,
a recently published study from Marchick, Kline and Jones determined that even non‐sustained
hypotension is associated with a threefold increased risk in mortality over no hypotension (43).
However, there remains a significant subset of patients who can initially present with normal
vital signs, and then progress to rapid cardiopulmonary collapse (44), thus making reliance on
vital signs an inadequate mode of disease detection.

Laboratory Results
More recently, recognition of sepsis syndrome has conventionally been linked to its
defining criteria (42), as well as enrollment criteria in clinical trials. Among many laboratory
data, clinicians use white blood cell count, particularly leukocytosis and bandemia, as an
indication of the presence of a bacterial infection, though leukopenia and neutropenia have also
been predictive of outcomes in severe sepsis (20). Extreme abnormalities in these values have
been associated with mortality, yet they have minor predictive value when compared to other
prognostic indicators and have poor accuracy in including or excluding bacterial infection (45‐
50).
Initially, hemoglobin and hematocrit values may be elevated, indicating
hemoconcentration due to severe hypovolemia (20). These measurements will likely trend
down with fluid resuscitation. Conversely, thrombocytopenia, which is a harbinger of
disseminated intravascular coagulation (DIC), is independently predictive of poor outcomes (51).
Furthermore, the Recombinant Human Activated Protein C Worldwide Evaluation in Severe
Sepsis (PROWESS) study detected a prolonged prothrombin time and elevated D‐dimer in 93.4%
and 99.7% of patients with severe sepsis, respectively (23, 52). Given this, it is recommended
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that clinicians obtain a platelet count and prothrombin time in patients suspected of severe
sepsis, adding further coagulation factor studies, such as D‐dimer, activated partial
thromboplastin time, fibrinogen and fibrin degradation products, when suspicious of DIC (20).
Lactic acidosis, or high serum lactate levels with metabolic acidosis, in the ED, as well as
upward trending lactate levels, have also been predictive of poor outcomes and may be
followed serially to evaluate response to therapy (53‐58). Elevations in lactate have several
etiologies including acute tissue hypoperfusion and anaerobic metabolism (59), augmentation of
lactate production by pathways involving catecholamines (60‐62), derangements in pyruvate‐
dehydrogenase enzyme activity (63) and reduction in lactate clearance due to hepatic
dysfunction (64, 65).
Evaluating lactate clearance as a predictor of mortality, Nguyen et al. revealed an 11%
decreased likelihood of mortality for each 10% increase in lactate clearance in an ED sepsis
study. In other words, at least a 10% lactate clearance during the first six hours in the ED
correlates with better survival outcomes. Arnold and others observed a 60% mortality rate in
patients with severe sepsis who did not clear lactate during protocol‐guided quantitative
resuscitation as compared to 19% in patient who did clear lactate, indicating that lactate
clearance is an independent predictor of death (66). Howell and colleagues further concluded
that lactate is a significant predictor of 28‐day mortality independent of blood pressure and
provides prognostic information superior to that conveyed by hemodynamic status and co‐
morbidities (58).
Finally, the acquisition of blood cultures before antibiotic administration to optimize
pathogen isolation is also a recommended practice when sepsis is suspected, as they will guide
antimicrobial therapy. Although cultures will only be positive in approximately 50% of patients
with severe sepsis/septic shock (67), it is a necessary diagnostic test which should be performed
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on all patients. Other laboratory results may illuminate specific organ dysfunctions and are
highlighted in the section below.

Assessment of Organ Dysfunction
Multiple organ dysfunction caused by circulatory derangements is a harbinger of
mortality in patients with severe sepsis and septic shock. Currently, it is recommended that
clinicians perform organ failure assessments on patients, as prior literature evaluating the
Multiple Organ Dysfunction Score (MODS) and Sequential Organ Failure Assessment (SOFA)
score correlates severity of ICU organ dysfunction with outcome (19, 68, 69). In 1995,
originators of the MODS reviewed literature from 1969 to 1993 to derive this severity of illness
scoring system that was found to correlate in a graded fashion with ICU mortality rate. With a
maximum score of 24, patients with MODS of 9 to 12 points had an approximately 25% ICU
mortality rate, 50% at 13 to 16 points, 75% at 17 to 20 points and 100% at greater than 20
points (68).
The MODS study goes on to describe the various organ dysfunctions identified in the
foundational literature. Respiratory dysfunction is identified by variables signifying impaired
oxygen exchange, such as Po2/Fio2 ratio, and those necessitating mechanical ventilation or
positive end‐expiratory pressure (PEEP). Of the two, the Po2/Fio2 ratio emerged as the optimal
descriptor, limited by oscillations in this parameter with interventions (68).
Acute respiratory distress syndrome (ARDS), a syndrome of diffuse lung parenchyma
injury causing noncardiogenic pulmonary edema, occurs with high frequency in septic patients
and results in hypoxic respiratory failure (70). ARDS is a clinical diagnosis defined by the
American‐European Consensus Conference (71). Criteria include acute onset, PaO2/FiO2 <200
regardless of PEEP, bilateral infiltrates and pulmonary capillary wedge pressure (PCWP) <18 mm
Hg (71).
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Renal dysfunction, or acute kidney injury, is defined as reduced urine output or the need
for dialysis to maintain homeostasis of fluid, electrolytes or acid‐base parameters, as well as by
increasing serum creatinine, with the latter being a sufficient indicator. Hepatic dysfunction is
indicated by jaundice, hyperbilirubinemia, decreased albumin or elevations in transaminases,
alkaline phosphatase or lactate dehydrogenase. Despite the fact that none of these emerged
singly or in combination as a superior variable, the study relied on hyperbilirubinemia as an
indicator of organ failure, even though its presence may denote other disease processes (i.e.
cholangitis, hemolysis, etc.) as opposed to primary liver dysfunction (68).
Indicators of cardiovascular dysfunction vary considerably and include hypotension,
need for inotropic support, increased left‐ or right‐sided filling pressures, dysrhythmias, serum
biomarker elevations and cardiac arrest. Minimum systolic blood pressure (SBP) <80 mmHg
demonstrated the highest correlation with ICU mortality rate (as high as 58% mortality when
SBP <50 mmHg). However, SBP is very susceptible to transient fluctuations with therapy and is
non‐specific for intrinsic cardiovascular dysfunction (a concern that is now offset by the
common use of cardiac enzymes such as troponin). Thrombocytopenia was the most frequent
marker of hematologic dysfunction likely due to disseminated intravascular coagulation (DIC).
But studies have also reported leukopenia or leukocytosis, anemia, increased prothrombin time
(PT) or partial thromboplastin time (PTT), disseminated intravascular coagulation (DIC) or fibrin
degradation products as signs of hematologic failure(68).
In defining neurologic dysfunction, many authors employed subjective criteria, including
confusion, psychosis, coma and decreased responsiveness, as well as the Glasgow Coma Scale
(GCS) and presence of meningitis or intracerebral hemorrhage. The MODS is generated using
the GCS values. Finally, even though gastrointestinal dysfunction was included in many of the
clinical investigations, it was omitted from the MODS because of difficulties in isolating a reliable
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descriptor. Some contenders include stress bleeding, which is now less common in the ICU, as
well diarrhea, enteral feeding intolerance, volume of nasogastric drainage, pancreatitis,
acalculous cholecystitis, bowel perforation and necrotizing enterocolitis. Endocrine and
immunologic dysfunctions were also omitted due to infrequent citation in the literature (68).
In like manner, the SOFA score, also developed as a mortality predictive tool for critically
ill patients, incorporated PaO2/FiO2 ratio (respiratory variable), platelet count (coagulation
variable), bilirubin (hepatic variable), hypotension (cardiovascular variable), Glasgow Coma
Score (neurologic variable) and creatinine or urine output (renal variable) (69). Initial, peak and
mean SOFA scores (measured zero through 24) calculated upon ICU admission and every 48
hours thereafter, correlated well with mortality. For example, initial and peak scores of more
than 11 or mean scores more than five correlated with >80% mortality rates. Moreover, the
score was better at discriminating mortality rates within the first 48 hours of ICU stay. Jones,
Trzeciak and Kline recently determined that the change in SOFA score from time zero (calculated
at ED recognition of illness) and 72 hours after intensive care admission also had a positive
correlation with mortality (72).
Beyond scores incorporating organ failure into survival prediction models, no study had
directly evaluated the relationship between end‐organ damage and critically ill septic patients in
the Emergency Department until the 2006 secondary analysis of an observational cohort by
Shapiro et al. (14). They affirmed that the mortality rate increased with the number of organ
dysfunctions noted in the ED as follows: no organ dysfunction (1.0% mortality), one organ
dysfunction (5.9% mortality), two (12.5% mortality), three (25.9% mortality), and four or more
(53.3% mortality). Of importance, this study only evaluated dysfunctions of six organ systems
including renal, cardiovascular, respiratory, central nervous, hematological and metabolic.
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Additionally, these results reflect fatal outcomes prior to the implementation of current
therapeutic standards (i.e. early goal‐directed therapy).
In short, the MODS study identified fundamental criteria to define organ failure in
severe sepsis. Furthermore, both the MODS and SOFA score solidified the relationship between
organ dysfunction mortality. Despite this significant contribution, the MODS and SOFA score
were derived from ICU data in critically ill patients, not in septic patients presenting to the
Emergency Department, as a means of evaluating severity of illness. Shapiro and colleagues
recognized this limitation and conducted a study that confirmed a positive correlation between
cumulative organ failure and mortality. However, to our knowledge, this study is the only one of
its kind. Additionally, despite the overwhelming evidence linking organ dysfunction and
mortality, a formal assessment of dysfunction in each of the organ systems in a patient
suspected of severe sepsis is not uniformly performed in the ED. Therefore, continued research
with the aim of translating this knowledge to clinical practice is much needed.

Global Scoring Systems
While the MODS and SOFA score both employ organ failure as the sole variable in
predicting outcomes, several ICU‐derived models have been developed that also integrate other
parameters such as laboratory data, age and past medical history. As such, the Acute Physiology
and Chronic Health Evaluation (APACHE) II classification is most often utilized scoring system for
critically ill patients in studies published over the last decade. It is a point system that relies on
12 physiologic variables including, temperature, mean arterial pressure (MAP), respiratory rate,
oxygenation, arterial pH, serum sodium, serum potassium, serum creatinine, hematocrit, white
blood count and Glasgow Coma Scale (73). By design, the APACHE II score is utilized 72 hours
into the hospitalization to predict outcome.
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Only limited studies have evaluated the influence of APACHE II scores in the ED, as the
APACHE II assessment typically requires information that is not readily available in a patient’s
first hours of presentation. One such small sepsis study from Nguyen and others demonstrated
that higher APACHE II scores measured at the time of ED admission were associated with
nonsurvivors, but the APACHE II score predicted mortality approached actual in‐hospital
mortality at 12 hours after ED admission. Additionally, hourly decreases in the score were
significantly greater in the ED than at any other time during the hospital stay in surviving group
(74). While these data support early, ED‐based interventions in septic patients, sufficient
information to conclude that APACHE II is a generalizable technique to risk stratify and delineate
specified treatment regimens for septic Emergency Department patients does not exist. Thus, it
is not current standard of practice to clinically estimate the APACHE II score in ED patients.
Another system in the theoretical stage of development is the Predisposition, Infection,
Response and Organ dysfunction (PIRO) sepsis staging classification introduced at the 2001
International Sepsis Definition Conference (19). This conceptual system models the TMN
approach to cancer with the understanding that a useful staging system takes into account a
patient’s baseline characteristics, as well as the potential to respond to therapy (19).
Predisposition concerns the co‐morbidities that modify both the disease process and the
approach to therapy, thus having a considerable effect on outcomes. Previous studies have
found an association between specific co‐morbid conditions, including cancer, cirrhosis,
congestive heart failure and HIV infection, and poorer outcomes in sepsis (75, 76). For example,
one study observed a two‐fold increase in the risk of death in sepsis patients with cancer
compared to those without cancer, a risk that is also seen in septic patients with HIV (76).
Other factors affecting approach to therapy would be cultural and religious beliefs and norms of
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the patient and his/her family, which are often very difficult to quantify in an effort to translate
these factors to clinical use.
Within the PIRO system, infection takes into account recent data that suggest that
pneumonia and intra‐abdominal infections have higher rates of mortality than other sources, as
well as the discovery that secondary nosocomial bacteremia may be more lethal than primary or
catheter‐related bacteremia (77). Similarly, there is evidence proposing that there are
differences in the endogenous host response to gram‐positive microbes as compared to gram‐
negative organisms (78). Regarding the host’s response, which has been difficult to characterize,
current therapies such as hemodynamic optimization, steroids and drotrecogin alfa (activated)
generally target this factor (19). Finally, organ dysfunction in septic patients parallels the
presence of metastatic disease in cancer patients within the TMN system.
In response to the need for an easily applicable, Emergency Department‐derived scoring
system, Shapiro and colleagues developed the Mortality in Emergency Department Sepsis
(MEDS) score, which is organized according to the PIRO framework (50). In this derivation and
validation study, nine variables independently associated with outcome, defined as 28‐day
mortality, were identified. The MEDS score utilizes clinical variables that are readily available to
ED physicians such as terminal illness, tachypnea or hypoxia, septic shock, platelet count, band
proportion >5%, age >65, lower respiratory infection, nursing home residence and altered
mental status (see Table 1). Once the MEDS score parameters were determined, the clinical
prediction rule stratified patients into five mortality risk groups indicating severity of illness: very
low (MEDS 0‐4), 1.1%; low (MEDS 5‐7), 4.4%; moderate (MEDS 8‐12), 9.3%; high (MEDS 12‐15),
16%; and very high (MEDS >15), 39%, in the validation set.
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Table 1. Mortality in Emergency Department
Sepsis (MEDS) Score
Points
Rapidly terminal co‐morbid illness*
Age > 65 years
Bands > 5%
Tachypnea or hypoxemia
Septic shock
Platelet count <150,000 mm3
Altered mental status
Nursing home resident
Lower respiratory infection

6
3
3
3
3
3
2
2
2

*Terminal illness is defined as metastatic cancer
or a disease condition with a >50% likelihood of
predicted fatality within 30 days.

The MEDS score was later externally validated by several small studies. One study
stratified patients into high‐risk (MEDS 12‐27) or low‐risk (MEDS <12) and discovered that high‐
risk patients had a significantly higher 28‐day mortality of 48.9% versus 17.5%, which was a
substantially better discriminatory tool than the APACHE II score (79). Another study showed
that the MEDS score has superior prognostic test performance compared to the Confusion Urea
Nitrogen Respiratory Rate Blood Pressure 65 Years or Older (CURB‐65) score and the Rapid
Emergency Medicine Score (REMS) (80).
In a small investigation comparing the MEDS score to biomarkers C‐reactive protein
(CRP) and procalcitonin (PCT), MEDS score had better prognostic accuracy than either in
predicting short‐term (5‐day) mortality, as well as identifying those at risk for late (6‐30 day)
mortality (81). However, MEDS score was more specific and less sensitive than PCT for early and
late mortality. Finally, a four‐hospital prospective external validation of the MEDS score showed
mortality rates stratified similarly to the Shapiro et al. study, ranging from 0.6% to 40% in
increasing progression (82).
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Despite these affirmative results, the MEDS score performed poorly in one prospective
study of EGDT (83). The most notable insufficiency occurred in the moderate ranges (5‐15) of
the MEDS score, where mortality was consistently underestimated. This study may have been
limited by several factors including size and the post hoc nature of the application of the score.
As a secondary analysis that included only 143 patients, the study may be insufficiently powered
to demonstrate with accuracy the predictive value of the MEDS score. Furthermore, had it been
employed prospectively in critical decision‐making such as disposition from the ED, the MEDS
score might have performed better.
Though further validation is needed, the MEDS score is largely considered the most
promising Emergency Department‐derived scoring system specifically for patients with sepsis
syndrome. While this risk stratification method has performed well overall in clinical trials to
determine illness severity, the MEDS score has not yet translated to the bedside. Therefore,
continued progress toward a projection tool for septic patients in the ED to aid in critical clinical
decisions, such as disposition and use of risky treatments, is necessary.

Treatment Recommendations
Early Antibiotics
The Surviving Sepsis Campaign recommendations state that “intravenous antibiotic
therapy should be started within the first hour of recognition of severe sepsis,” though in
practice administration of antibiotics takes several hours (16). This standard was established
based on data from a retrospective investigation of 2731 patients with septic shock that
determined that survival was inversely proportional to time of administration of antibiotics, with
an approximately 8% per hour absolute decline (84). Furthermore, time to initiation of
antibiotic therapy was the superior marker for outcomes.
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As equally important to the timing of antibiotics is the appropriate selection of empiric
therapy. In one study, appropriate antibiotics started empirically to cover potential pathogens
reduced mortality from 34% to 20% in bacteremic patients. The odds ratio for fatality with
inappropriate coverage was 1.6 (85). Despite limited availability of some key factors informing
which antimicrobial to administer in the ED setting, ED practitioners have the supremely
important responsibility of dispensing appropriate and timely antibiotic treatments to reduce
sepsis‐related mortality.

Source Control
In addition to the timely and accurate usage of antibiotics, elimination of infectious foci
limits host exposure to the pathogen. Some bacteria evade antimicrobial eradication by
adhering to synthetic medical devices in protective biofilms (86). Infectious sites are usually
identified through history, physical exam and imaging studies and should be removed in the ED
when possible and safe for the patient; however, source control may necessitate invasive
measures such as abscess drainage or open procedures in the operating room (70).

Early Goal‐Directed Therapy
The concept of quantitative resuscitation, or hemodynamic optimization, as a treatment
strategy to improve outcomes in critically ill patients was first introduced by Shoemaker et al. in
a 1988 study of high risk surgical patients. In a later meta‐analysis of hemodynamic
optimization trials, Kern and Shoemaker determined that early, rather than later, therapeutic
hemodynamic interventions improve outcome by significantly reducing short‐term mortality
(87). Based upon these studies and other observations from goal‐directed therapy trials
performed on ICU patients, early goal‐directed therapy (EGDT) in the ED setting was evaluated
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in 2001 by Rivers and colleagues and served as the stimulus for a new generation of evidence‐
based clinical treatments for sepsis syndrome (24).
In contrast to previous trials enrolling patients later in the course of hospitalization, and
in concordance with the results from the Kern systematic review, early goal‐directed therapy
aims to optimize physiologic endpoints in the proximal stage of disease. This study initiated
therapies in the ED in a protocol that was executed for up to 6 hours prior to ICU admission.
Early goal‐directed therapy “involves adjustments of cardiac preload, afterload, and contractility
to balance oxygen delivery with oxygen demand” (24).
Two hundred and thirty‐six patients were randomized to the therapeutic or standard
arms of the study. The protocol under investigation was as follows:
“A 500‐ml bolus of crystalloid was given every 30 minutes to achieve a central venous
pressure of 8 to 12 mm Hg. If the mean arterial pressure was less than 65 mm Hg,
vasopressors were given to maintain a mean arterial pressure of at least 65 mm Hg. If
the mean arterial pressure was greater than 90 mm Hg, vasodilators were given until it
was 90 mm Hg or below. If the central venous oxygen saturation was less than 70
percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After
the central venous pressure, mean arterial pressure, and hematocrit were thus
optimized, if the central venous oxygen saturation was less than 70 percent,
dobutamine administration was started at a dose of 2.5 μg per kilogram of body weight
per minute, a dose that was increased by 2.5 μg per kilogram per minute every 30
minutes until the central venous oxygen saturation was 70 percent or higher or until a
maximal dose of 20 μg per kilogram per minute was given. Dobutamine was decreased
in dose or discontinued if the mean arterial pressure was less than 65 mm Hg or if the
heart rate was above 120 beats per minute. To decrease oxygen consumption, patients
in whom hemodynamic optimization could not be achieved received mechanical
ventilation and sedatives” (24) (see Figure 2).
As stated, the protocol involved continuous invasive monitoring of various hemodynamic
parameters including CVP, ScvO2, and MAP. Outcomes measured by in‐hospital, 28‐day and 60‐
day mortality, were much improved, with rates of 30.5%, 33.3% and 44.3% respectively, versus
46.5%, 49.2% and 56.9% in the standard therapy group (24).
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Fiigure 2. Protocol for Early Goal‐Directed Therapy.
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20.3%, respectively (89). Similarly, a meta‐analysis from Jones and others also demonstrated a
decrease in mortality with EGDT (90), as well as numerous other studies that evaluated
mortality after implementation of EGDT in conjunction with other therapies in septic patients as
far as 1‐year out and in generalizable ED settings (11, 91). Despite these data, concerns remain
regarding the effectiveness of individual interventions that were bundled in the EGDT protocol
(92). Therefore, further validation of the EGDT protocol is planned through the multi‐center,
randomized, National Institutes of Health (NIH) – funded Protocolized Care of Early Septic Shock
(PROCESS) trial (20).

Activated Protein C
Activated protein C is a powerful anticoagulant, pro‐fibrinolytic, anti‐inflammatory and
anti‐apoptotic enzyme that is down‐regulated in sepsis (20). Given this, the PROWESS trial was
designed to investigate the utility of drotrecogin alfa (activated) in reducing 28‐day sepsis‐
related mortality (23). Investigators discovered that mortality rates were lowered from 30.8% in
the placebo group to 24.7% in the treatment group, with a relative reduction in mortality rate of
19.8%. Most notably, the drug was found to reduce absolute mortality by 13% in septic patients
with greater than or equal to two illness‐related organ dysfunctions or APACHE II scores greater
than or equal to 25 (23).
The Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis
(ADDRESS) trial revealed that less acute patients with single‐organ dysfunction or an APACHE II
score below 25 did not benefit from drotrecogin alfa (activated) (93). Furthermore, the
ADDRESS study also discovered that patients who had surgery within 30 days and single organ
dysfunction who received drotrecogin alfa (activated) had higher 28‐day mortality compared
with the placebo group. Other investigations suggest a modest benefit in mortality when
drotrecogin alfa (activated) is administered early in septic patients (94‐96).
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Furthermore, there are several absolute contraindications to the use of drotrecogin alfa
(activated) including: active internal bleeding, hemorrhagic stroke within three months, recent
intracranial or intraspinal surgery, severe head trauma within two months, trauma with an
increased risk of life‐threatening bleeding, presence of an epidural catheter, intracranial
neoplasm or mass lesion, evidence of cerebral herniation or known hypersensitivity to
drotrecogin alfa (activated) (20). However, it is still utilized in select patients with high severity
of illness scores who are not at risk for coagulopathic complications.

Mechanical Ventilation
Studies from the 1990s demonstrate that mechanical ventilation with lower tidal
volumes reduces mortality in patients with ARDS (97, 98). Later, the ARDSNET study enrolled
over 800 patients in a prospective multicenter design to compare ventilation with tidal volumes
of 6 cc/kg and 12 cc/kg of ideal body weight, where “permissive hypercapnea,” or a controlled
hypoventilation and mild respiratory acidosis (pH 7.30‐7.45), was tolerated in the reduced tidal
volume group (99). The study demonstrated a 9% absolute reduction in mortality in the
reduced tidal volume group when the plateau pressure was maintained below 30 cm H2O. This
was the largest and most successful trial to investigate lung‐protective ventilation in critically ill
patients and implementation of low tidal‐volume ventilation strategies is promulgated by sepsis
treatment guidelines (70). A subsequent study of the clinical translation of the ARDSnet
protocol discovered that there is much room for improvement in implementing this measure at
the bedside (100).

Tight Glucose Control
A prospective, randomized, controlled trial of patients in a surgical ICU demonstrated
that tight glucose control (i.e. maintaining blood glucose levels between 80 and 100 mg/dL)
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compared with conventional treatment reduced mortality by one‐third, particularly with respect
to deaths due to multiple organ failures (26). However, a more recent study of medical ICU
patients from the same lead author revealed no difference in mortality rates between intensive
and standard insulin therapy, though tight glucose control did reduce morbidity due to
prevention of acute kidney injury, accelerated weaning off ventilators and faster ICU and
hospital discharges (101). On the other hand, many other studies have reported high incidence
of hypoglycemia with tight glycemic control, a potentially lethal adverse consequence in
critically ill populations (102).
Intensive insulin therapy is not a standard intervention not only because of the
conflicting data, but also because none of these studies have been conducted specifically on
patients with severe sepsis/septic shock (20). To aid in the debate, Wiener, Wiener and Larson
conducted a meta‐analysis of the randomized controlled trials that investigated glycemic control
in critically ill patients, as well as conducted subgroup analyses of both glucose goals (≤110
mg/dL or <150 mg/dL) and ICU settings (surgical, medical or all critically ill patients) (102).
Within the 29 randomized controlled trials including a total of 8,432 patients, hospital mortality
rates did not differ between tight glucose control and standard groups. Furthermore, there was
no significant mortality difference when patients were stratified by glucose goal or intensive
care setting. The study also determined that tight glucose control was associated with
diminished risk of septicemia and a higher risk of hypoglycemia (102). Thus, further
investigation in this area is necessary before practice guidelines can be established.

Steroids
Part of the physiologic response to sepsis is a surge in stress hormones such as cortisol.
However, high levels of cytokines in septic patients can inhibit cortisol synthesis and induce
corticosteroid resistance in tissues (103‐105). Septic patients can have poor responses when
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challenged with adrenocorticotropic hormone (ACTH) or corticotrophin‐releasing hormone in
the setting of deficient adrenal reserve. Relative adrenal insufficiency is defined as an increase
in serum cortisol of less than or equal to 9 mg/dL one hour after administration of 250mg of
ACTH (20).
Poor adrenal reserve has been linked to higher mortality rates and protracted
vasopressors requirements (106). Prior to the 2002 study from Annane et al. (25), investigations
did not demonstrate a beneficial effect of pharmaceutical grade corticosteroids in patients with
septic shock (107‐109). However, Annane and colleagues found a relative reduction in 28‐day
mortality rate of 16% (63% in the placebo group as compared to 53% in the treatment group) in
severely ill patients with septic shock and inadequate adrenal reserve with administration of
corticosteroids. Time on vasopressors was also reduced when treated with low‐dose
corticosteroids.
On the contrary, patients with adrenal responsiveness had a non‐statistical increase in
mortality rates when treated with corticosteroids, a factor that may prove problematic with this
treatment option (25). Given that the majority of ED patients maintain appropriate adrenal
function, the use of corticosteroids is not recommended unless frank adrenal insufficiency is
suspected (20). Recently, the European‐based multicenter Corticosteroid Therapy of Septic
Shock (CORTICUS) trial did not validate the efficacy to low‐dose corticosteroid use in septic
patients and even showed that the incidence of superinfection may increase with steroid
therapy (110). Therefore, in the ED setting, corticosteroids should only be utilized when there is
a high suspicion of adrenal insufficiency in combination with vasopressor dependence (17).

Summary
Severe sepsis is a critical illness with a vital impact on affected patients, Emergency
Departments and the health care system as a whole. It is a disease of our nation’s fastest
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growing population, the elderly, affecting both men and women nearly equally. Due to the
cryptic nature of the illness and lack of definitive biomarkers, definitions of sepsis syndrome are
derived from consensus conferences. These definitions reflect some of the key
pathophysiological processes in the progress of illness leading to global tissue hypoxia and end‐
organ failure.
Because the physiologic determinants of health outcomes are likely established early in
the course of severe sepsis and septic shock, advancements in the two phases of management,
early identification and early intervention, in Emergency Department settings are critical factors
in reducing mortality. An accurate method of risk stratifying patients with severe sepsis and
septic shock will optimize the selection of critical ED interventions and ICU resources in high‐risk
patients (111).
Toward this end, continued ED‐based investigation of early predictors of poor outcomes
in patients with sepsis syndrome is essential. One very important candidate for inclusion in risk
stratification schemes is cumulative organ dysfunction. While organ injury is a long established
cause of death in septic patients, studies evaluating cumulative organ dysfunction upon
presentation to the ED as a predictor of mortality are extremely limited. Moreover, no clinical
investigation assessing the predictive value of cumulative organ injury in patients receiving
currently recommended treatments such as early‐goal directed therapy, vasopressors and
mechanical ventilation exists, thus providing an opportunity for future research.
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Hypothesis and Aims of Research
Hypothesis
Increasing cumulative organ dysfunction in patients presenting to the Emergency
Department with severe sepsis and septic shock correlate with post‐Emergency Department
deterioration as defined by in‐hospital mortality, mechanical ventilation requirement and
vasopressor use within 72 hours of presentation.

Aims of Research
The primary aim of this study is to:
1. Evaluate cumulative organ dysfunction as a predictor of short term (28‐day) and total in‐
hospital mortality.
Secondary aims of the study are to:
1. Evaluate cumulative organ dysfunction as a predictor of short‐term vasopressor
dependence within 72 hours of presentation to the Emergency Department;
2. Evaluate cumulative organ dysfunction as a predictor of mechanical ventilation during
hospitalization;
3. Elucidate differences in patients with high cumulative organ dysfunction scores (≥5) and
low cumulative organ dysfunction scores (<5); and
4. Externally validate the Mortality in Emergency Department Sepsis (MEDS) score.
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Methods
Involvement
This study is a continuation of a project originally designed by the Principal Investigator
(PI), Charles R. Wira, III. It has been approved by the Department of Emergency Medicine
Research Committee at Yale School of Medicine, as well as the Human Investigation Committee
(HIC). An amendment was made in 2009 to the original 2007 HIC project proposal to add this
author, Martina Sanders‐Spight, as a clinical investigator on the project. Two other students,
Melissa Wollan and Sundeep Bhat, worked with the severe sepsis registry containing the data
used in this project in preceding years. Additionally, residents in the Department of Emergency
Medicine have also contributed data to the severe sepsis registry. However, the research
question under investigation by this author is original and independent of those asked by the
previous student clinical investigators.
The PI has been responsible for the long‐term management of the registry, facilitating
approval of the project by the HIC and Department of Emergency Medicine Research
Committee, guiding the data analysis and contributing greatly to the substance of the research
and scientific thought. This author is responsible for data abstraction and data entry, as well as
calculating the Mortality in Emergency Department Sepsis (MEDS) scores for the last 109
patients added to the registry. This author also conducted statistical analyses under the
supervision of the PI using statistical calculators (“GraphPad Quick Calcs” software) and
generated all tables and figures in this report, unless otherwise cited.

Subjects
This study is a retrospective chart review of patients selected from an interdisciplinary
severe sepsis registry comprised of patients at Yale – New Haven Hospital in New Haven, CT and
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the satellite site in Guilford, CT, who presented to the Emergency Department (ED) with severe
sepsis and septic shock between July 1, 2005 and September 5, 2009. The main ED in New
Haven serves an urban, academic hospital and treats approximately 75,000 patients per year.
The principal investigator used clinical suspicion, not otherwise specified, to select patients who
were suspected of meeting criteria for severe sepsis or septic shock at the time of presentation
to the Emergency Department. This author performed an in‐depth review of each patient’s
medical records to determine eligibility in this study.

Inclusion Criteria
All patients included in this study are at least 18 years of age, meet at least two of four
criteria for Systemic Inflammatory Response Syndrome (SIRS), have a documented suspicion of a
source of clinical infection, as well as at least one newly diagnosed organ dysfunction in the
Emergency Department (see Table 2).

Exclusion Criteria
Patients were excluded from the study if there were less than 18 years old, did not meet
criteria for severe sepsis or septic shock, were discharged to home directly from the Emergency
Department or had documentation of comfort measures only.

Data Collection
Patient identification numbers were assigned by the principal investigator prior to chart
review. Data were extracted from patient medical records using a standardized data collection
form designed by the principal investigator and previous student clinical investigators (see
Appendix). Under the faculty PI’s supervision, the entire patient record in either electronic or
paper form chronicling the visit included in the study was used for abstraction. Electronic
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medical records were obtained via “Chart View,” “Lynx Medical Systems” and “Sunrise Clinical
Manager.”

Table 2. Inclusion Criteria.*
1.
2.

At least 18 years of age
Meets criteria for severe sepsis as follows:
a. Two or more criteria for the Systemic Inflammatory Response Syndrome (SIRS), including:
 Body temperature >100.4°F or <96.8°F
 Heart rate >90 min‐1
 Respiratory rate >20 min‐1 or a PaCO2 of <32 mm Hg
 White blood cell count of >12,000 cells μL‐1 or <4,000 cells μL‐1 or > 10% immature
neutrophils
b. Documented suspicion of a source of infection, including any one of the following:
 White blood cell count of >10,000 cells μL‐1 or <4,000 μL‐1 or > 10% immature neutrophils
 Body temperature >100.4°F or <96.8°F
 Blood cultures drawn in the Emergency Department
 Antibiotics administered in the Emergency Department
 Documentation of presumed source of infection in the Emergency Department
c. A least one newly diagnosed organ dysfunction in the Emergency Department, including:
 Transient systolic BP <90 mmHg that responds to fluid resuscitation
 Lactate level > 2mmol/mL
 Unexplained acidosis (pH < 7.35) or a serum bicarbonate < 21
 Altered mental status (change from baseline)
 Platelets <150,000mm3 (no history of thrombocytopenia)
 Elevation of bilirubin above normal or either direct or indirect bilirubin > than baseline
 High coagulation factors (any elevation in absence of heparin or Coumadin use)
 Acute Renal Failure (Cr >0.5 from baseline, or abnormal if no baseline available)
 Hypoxemia (oxygen saturation less than 90% or change in oxygen requirement)
 Troponin elevation above baseline

*Adapted for the 2001 Sepsis Definitions Conference (19).

After review of medical records, data were first recorded on the data collection form,
then transferred by this author into a Microsoft Excel database previously used by student
clinical investigators, adding to the severe sepsis registry. As required by the Yale HIC, all
protected identifying health information was kept separately from the data collection forms in a
password‐protected spreadsheet accessible to only this author, other clinical investigators and
the principal investigator. Data collection forms were kept in a locked cabinet by the faculty PI.
Prior students collected 514 overlapping data points on patients with 95% precision,
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demonstrating a reliable method of data extraction and entry from the source patient’s medical
records.
Elements of medical records that were reviewed include all available Emergency
Department documents, hospital laboratory data, clinician admission and progress notes,
nursing flow sheets and discharge summaries. Abstracted data included demographic
information about patients such as age, gender and residence in a nursing home or extended
care/group living facility. Vital signs during Emergency Department stay, including systolic blood
pressure, diastolic blood pressure, heart rate, respiratory rate, temperature, oxygen saturation
and oxygen requirement were also recorded. Heart rate, systolic blood pressure and diastolic
blood pressure were recorded until discharge or the start of vasopressors. Vital signs recorded
after the initiation of vasopressors in the Emergency Department were not included in the
database, nor were they used for calculations in this study.
Other clinical data gathered from the Emergency Department stay included the Glasgow
Coma Scale, ED arrival and departure times, calculated total ED length of stay, amount of fluids
and time to administration, type of antibiotics and time to administration, source of microbial
cultures, appropriateness of antibiotics based on microbial culture susceptibilities, past medical
history and documentation of early goal‐directed therapy in the ED. Documentation of early
goal‐directed therapy included the presence of a central line and time initiated, central venous
pressure initial value and time plus peak measurement and central mixed venous oxygen
saturation initial value and time, as well as recordings during the first 24 hours of
hospitalization.
Laboratory data included final microbial culture results, including blood, urine and other
cultures taken, white blood cell count, percentage bands, hematocrit, platelets, serum sodium,
serum chloride, serum potassium, serum bicarbonate, blood urea nitrogen, serum creatinine,
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cardiac troponins, direct and indirect bilirubin, international normalized ration (INR),
prothrombin time (PT) and partial prothrombin time (PTT) measured initially in the ED.
Additionally, initial and peak lactate levels in the Emergency Department and upon admission to
the floors, as well as arterial blood gas results in the Emergency Department were recorded.
Lab values were considered abnormal if they exceeded previously established normal values at
Yale‐New Haven Hospital.
Use of vasopressors and timing of administration, specifically less than or greater than
72 hours after presentation, were determined from the ED and intensive care unit (ICU) nursing
flow sheets and discharge summaries. Vasopressors included in this study were norepinephrine,
dopamine, vasopressin, epinephrine and phenylephrine. Inotropes such as dobutatmine and
digoxin were also recorded. Other therapies and interventions used and location administered,
such as corticosteroids, source control, mechanical ventilation, tight glucose control, blood
products and activated protein C, were also recorded. Vasopressor, inotrope and mechanical
ventilator use were used as direct outcomes measures for this analysis.
Finally, disposition from the ED, diagnoses of attending emergency physician, final
diagnosis upon discharge from the hospital, initial and total ICU length of stay, total hospital
length of stay, initial and total time intubated, were documented. Of note, the ICU and hospital
length of stay and mechanical ventilation length data were recorded for the last 109 patients
only, which this author collected.

Assessment of Severe Sepsis and Septic Shock
Each patient included in this study had at least two of four SIRS criteria and evidence of
a suspected infection based on presence of at least one of the following: white blood cell count
greater than 10,000 cells μL‐1, temperature >100.4⁰F or <96.4⁰F, blood cultures obtained in ED,
antibiotics administered in ED or suspected source of infection based on clinical exam or
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imaging results (see Table 2). Additionally, all patients had evidence of at least one end‐organ
dysfunction. Patients with no organ dysfunction, by definition having only sepsis (as opposed to
severe sepsis or septic shock), were not included in this study because they were excluded from
the registry since its inception.
Any patient who presented with or developed septic shock during their ED stay was also
included. Septic shock is defined as severe sepsis and a systolic blood pressure <90 mmHg that
is unresponsive to intravenous fluids. Patients in extremis (defined as an initial systolic blood
pressure <80 mmHg and/or requiring vasopressors within 15 minutes of presentation to ED)
were also included in this study.

Statistical Analysis
Previous thesis research from Yale Medical Student Melissa Wollan revealed a
statistically significant difference in mortality between patients with fewer than five and five or
more organ injuries (112). Based on this information, our experimental groups reflect this
finding and are delineated by five organ failures. Furthermore, in the evaluation of the MEDS
score, we employ a similar mortality risk grouping to that determined by the original derivation
study: very low (0‐4), low (5‐7), moderate (8‐12), high (12‐15) and very high (≥16) risk (50). The
one exception is that the very low and low risk groups are combined in our study to create a
zero to seven (0‐7) MEDS score group, as the difference in their mortality rates (0.9% versus
2.0%) was not statistically significant in the original study. Finally, alpha is set to 0.05.
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Results
Of the 640 charts reviewed for inclusion in the severe sepsis registry, 521 patients (81%)
met criteria for enrollment in our study. Included patients were divided into two experimental
groups, fewer than five organ dysfunctions (n=410 or 79%) and greater than or equal to five
organ dysfunctions (n=111 or 21%).
The 119 patients excluded from this study had a mean age of 63.9 years, with
approximately half (n=60) being male. None of the excluded patients were less than 18 years of
age, 12 (10%) had documented comfort measures only in the Emergency Department, 74 (62%)
met fewer than two SIRS criteria, 25 (21%) had sepsis only (meaning patients met criteria for
SIRS but had no documented end‐organ failure) and 18 (15%) were discharge to home directly
from the ED.

Patient Baseline Characteristics
Demographic information and co‐morbidities for all patients included in this study can
be found in Table 3. Overall, 256 (49.1%) of patients were male and 265 (50.9%) were female.
A statistically significant higher percentage of men than women had greater than or equal to
five organ failures (59.5% versus 40.5%, respectively; p=0.02). The mean age at presentation
was 63.1 ± 18.1 years, with a similar distribution in both the fewer than five and greater than
five organ injuries groups.
Of the 16 co‐morbid conditions reviewed in this study, only three demonstrated
differences between patients with either fewer than five or greater than/equal to five organ
dysfunctions, including residence in an extended care facility prior to admission (33.4% vs.
19.8%, respectively; p=0.005) and past medical history of liver disease (7.1% vs. 15.3%,
respectively; p=0.01) and congestive heart failure (20.7% vs. 31.5%, respectively; p=0.02). The
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rates of the remaining co‐morbidities, consisting of coronary artery disease, hypertension,
chronic obstructive pulmonary disease, asthma, end‐stage renal disease, diabetes mellitus,
alcohol abuse, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome
(AIDS), immunodeficiency not otherwise specified (NOS), cancer, cancer with chemotherapy,
cerebral vascular accident (CVA)/transient ischemic attack (TIA) and chronic altered mental
status, were not different between the two groups.

Table 3. Demographics and co‐morbidities.

All patients
(n=521)

<5 organ
dysfunctions
(n=410)

≥5 organ
dysfunctions
(n=111)

63.1 ± 18.1

63.1 ± 18.1

63.1 ± 18.2

256 (49.1)
265 (50.9)

190 (46.3)
220 (53.7)

66 (59.5)
45 (40.5)

159 (30.5)
46 (8.8)
120 (23.0)
120 (23.0)
282 (54.1)
97 (18.6)
31 (6.0)
60 (11.5)
173 (33.2)
49 (9.4)
33 (6.3)
46 (8.8)
95 (18.2)
47 (9.0)
78 (15.0)
62 (11.9)

137 (33.4)
29 (7.1)
85 (20.7)
87 (21.2)
226 (55.1)
82 (20.0)
26 (6.3)
50 (12.2)
133 (32.4)
33 (8.0)
25 (6.1)
39 (9.5)
75 (18.3)
34 (8.3)
63 (15.4)
50 (12.2)

22 (19.8)
17 (15.3)
35 (31.5)
33 (29.7)
56 (50.5)
15 (13.5)
5 (4.5)
10 (9.0)
40 (36.0)
16 (14.4)
8 (7.2)
7 (6.3)
20 (18.0)
13 (11.7)
15 (13.5)
12 (10.8)

p‐value*

Demographics
Age, mean years ± SD
Sex, n (%)
Male
Female

0.99
0.02

Co‐morbidities, n (%)
Nursing home resident**
Liver disease
Congestive heart failure
Coronary artery disease
Hypertension
COPD
Asthma
End‐stage renal disease
Diabetes mellitus
Alcohol abuse
HIV/AIDS
Immunodeficiency NOS
Cancer
Cancer with chemotherapy
CVA/TIA
Chronic altered mental status

0.005
0.01
0.02
0.07
0.39
0.13
0.65
0.41
0.5
0.06
0.66
0.35
1.0
0.27
0.76
0.87

SD, standard deviation; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus;
AIDS, acquired immune deficiency syndrome; NOS, not otherwise specified; CVA, cerebral vascular accident; TIA,
transient ischemic attack
*Bolded p‐values are <0.05 and considered statistically significant.
**Includes any variation of extended care facility or group home living.
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Disease severity classifications and cumulative organ dysfunction characteristics are
detailed in Table 4. Four hundred and thirty five cases or 83.5% were classified as severe sepsis
and 86 or 16.5% as septic shock. The mean number of cumulative dysfunctional organ systems
for all patients was 3.2 ± 1.8, with survivors having 2.9 ± 1.6 versus 4.5 ± 2.3 mean organ failures
in nonsurvivors (p<0.0001). Stratified further, 229 (44.0%) patients had one or two
dysfunctional organ systems, 181 (34.7%) had three or four, 77 (14.8%) had five or six and 34
(6.5%) had greater than or equal to seven organ injuries.

Table 4. Disease severity classification and cumulative organ dysfunction.

All patients
(n=521)

<5 organ
dysfunctions
(n=410)

≥5 organ
dysfunctions
(n=111)

p‐value*

435 (83.5)
86 (16.5)

366 (89.3)
44 (10.7)

69 (62.2)
42 (37.8)

<0.0001
<0.0001

Disease severity classification, n (%)
Severe sepsis
Septic shock
Cumulative organ dysfunction, mean ± SD

3.2 ± 1.8

Survivors**
Nonsurvivors**

2.9 ± 1.6
4.5 ± 2.3

<0.0001

Number of end‐organ dysfunctions, n (%)
1 or 2
3 or 4
5 or 6
7 or more

229 (44.0)
181 (34.7)
77 (14.8)
34 (6.5)

Specific end‐organ dysfunctions, n (%)
Transient hypotension
Elevated lactate
Unexplained acidosis
Altered mental status
Thrombocytopenia
Hyperbilirubinemia
Abnormal coagulation studies
Acute renal failure
Hypoxemia
Troponin elevation

194 (37.2)
238 (45.7)
230 (44.1)
164 (31.5)
78 (15.0)
186 (35.7)
74 (14.2)
208 (39.9)
158 (30.3)
120 (23.0)

117 (28.5)
151 (36.8)
141 (26.1)
107 (26.1)
35 (8.5)
106 (25.9)
26 (6.3)
116 (28.3)
115 (28.0)
64 (15.6)

77 (69.4)
87 (78.4)
89 (80.2)
57 (51.4)
43 (38.7)
80 (72.1)
48 (43.2)
92 (82.9)
43 (38.7)
56 (50.5)

SD, standard deviation
*Bolded p‐values are <0.05 and statistically significant; **p<0.0001 when comparing mean number of
cumulative organ dysfunctions among survivors and nonsurvivors.

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.04
<0.0001
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All specific organ systems had statistically significant differences in incidence between the two
experimental groups.

Features of the Disease
Data regarding SIRS criteria, suspected source of infection and presumed site of
infection are included in Table 5. All parameters of both SIRS criteria and suspected source of
infection were equivalent, except white blood cell (WBC) count. Seventy‐seven percent (77%) of
patients with higher cumulative organ dysfunction compared with 66.1% of patients in the other
group had elevated WBC counts meeting SIRS criteria (p=0.04).

Table 5. SIRS criteria and suspected source of infection.

All patients
(n=521)

<5 organ
dysfunctions
(n=410)

≥5 organ
dysfunctions
(n=111)

p‐value*

282 (54.1)
447 (85.8)
410 (78.7)
356 (68.3)

219 (53.4)
349 (85.1)
320 (78.0)
271 (66.1)

63 (56.8)
98 (88.3)
90 (81.1)
85 (76.6)

0.59
0.45
0.52
0.04

401 (77.0)
282 (54.1)
475 (91.2)
466 (89.4)
331 (63.5)

304 (74.1)
219 (53.4)
371 (90.5)
363 (88.5)
262 (63.9)

97 (87.4)
63 (56.8)
104 (93.7)
103 (92.8)
69 (62.2)

0.003
0.59
0.35
0.23
0.74

158 (30.3)
82 (15.7)
55 (10.6)
34 (6.5)
41 (7.9)

130 (31.7)
64 (15.6)
39 (9.5)
31 (7.6)
28 (6.8)

28 (25.2)
18 (16.20
16 (14.4)
3 (2.7)
13 (11.7)

0.20
0.88
0.16
0.08
0.11

SIRS criteria, n (%)
Temperature
Heart rate
Respiratory rate
White blood cell count**
Suspected source of infection, n (%)
White blood cell count***
Temperature
Blood cultures drawn in ED
Antibiotics administered
Presumed site of infection
Presumed site of infection, n (%)
Pulmonary
Genitourinary
Abdominal
Soft tissue
Other

SIRS, systemic inflammatory response syndrome; ED, emergency department
*Bolded p‐values are <0.05 and considered statistically significant.
**White blood cell count >12,000 cells μL‐1 or <4,000 cells μL‐1 or > 10% immature neutrophils.
*** White blood cell count >10,000 cells μL‐1 or <4,000 cells μL‐1 or > 10% immature neutrophils.
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Similarly, 87.4% versus 74.1% of patients in the greater than/equal to five and fewer
than five organ failures groups, respectively, had elevated WBC counts as a measure for
suspected infection (p=0.003). Of note, the two criteria differ in that SIRS requires a WBC count
is >12,000 cells μL‐1, while the suspected source of infection requirement is WBC count >10,000
cells μL‐1. Finally, both groups were comparable in the distribution of presumed sites of
infection.
Information regarding initial laboratory findings and vital signs is documented in Table 6.
Despite disparities in the rates of elevated WBC counts, mean white blood cell counts and serum
sodium concentrations were comparable between the two groups. On the contrary, the fewer
than five and greater than or equal to five organ injuries groups diverge when evaluating mean
hematocrit (37.2% vs. 35.5%, respectively; p=0.03), bicarbonate (22.0 vs. 18.0, respectively;
p<0.0001), creatinine (2.0 vs. 3.0, respectively; p<0.0001) and elevated troponin (0.35 vs. 0.81,
respectively; p=0.02). Lactate levels also distinguish the groups with the fewer than five organ
failures group having an mean initial ED and floor lactate of 2.3 and 1.8, respectively, compared
to the greater than or equal to five organ failures group, which had mean initial ED and floor
lactates of 4.0 and 3.2, respectively (p<0.0001 in for both ED and floor values).
Both groups had similar percentages of total cultures sent, as well as blood and urine
cultures specifically. There was a difference in the number of other cultures sent, which include
sites like wound or central line, with 40.5% of the highly organ dysfunctional group compared to
29.3% of more mildly organ dysfunctional group (p=0.03). However, this did not have an impact
on the distribution of positive cultures. The more severely organ dysfunctional group had more
(57.4%) positive blood cultures of any kind compared to 43.8% in the other group (p=0.007).
Most of this difference is accounted for with positive blood cultures, as 18.1% of those sent
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from the fewer than five organ injuries group were positive versus 38.1% of the greater
than/equal to five organ injuries group (p<0.0001).

Table 6. Initial laboratory and vital signs data.

All patients
(n=521)

<5 organ
dysfunctions
(n=410)

≥5 organ
dysfunctions
(n=111)

p‐value*

14.8 ± 12.5
36.8 ± 7.0
135.4 ± 6.2
21.1 ± 5.4
2.2 ± 2.0
0.57 ± 1.06
2.7 ± 2.2
2.2 ± 2.3

14.4 ± 9.1
37.2 ± 6.5
135.7 ± 5.7
22.0 ± 5.0
2.0 ± 1.9
0.35 ± 0.50
2.3 ± 1.6
1.8 ± 1.7

16.2 ± 20.6
35.5 ± 8.5
134.6 ± 7.5
18.0 ± 5.7
3.0 ± 2.0
0.81 ± 1.4
4.0 ± 3.3
3.2 ± 3.2

0.19
0.03
0.12
<0.0001
<0.0001
0.02
<0.0001
<0.0001

496 (95.2)
480 (92.1)
350 (67.2)
165 (31.7)
232 (46.8)
108 (22.5)
94 (26.9)
88 (53.3)

388 (94.6)
375 (91.5)
267 (65.1)
120 (29.3)
170 (43.8)
68 (18.1)
75 (28.1)
64 (53.3)

108 (97.3)
105 (94.6)
83 (74.8)
45 (40.5)
62 (57.4)
40 (38.1)
19 (22.9)
26 (57.8)

0.32
0.33
0.07
0.03
0.007
<0.0001
0.4
0.73

94.2 ± 23.1
62.7 ± 16.5

98.0 ± 23.2
65.5 ± 16.4

80.6 ± 16.7
52.4 ± 12.4

<0.0001
<0.0001

Initial laboratory values, mean ± SD
White blood cell count
Hematocrit
Sodium
Bicarbonate
Creatinine
Elevated troponin
Initial ED lactate
Initial floor lactate
Cultures, n (%)
Total cultures sent
Blood
Urine
Other
Total positive cultures**
Blood
Urine
Other
Vital signs, mean ±SD
Lowest SBP
Lowest MAP

SD, standard deviation; ED, emergency department; SBP, systolic blood pressure; MAP, mean arterial
pressure
*Bolded p‐values are <0.05 and considered statistically significant.
**Coagulase negative staphylococcus, corynebacterium and mixed flora were all treated as contaminants in
accordance with hospital microbial patterns and were not considered positive results.

Key vital signs including systolic blood pressure (SBP) and mean arterial pressure (MAP)
also varied among the experimental groups. The mean SBP and MAP for the fewer than five
organ failures group were 98.0 and 65.5, respectively, compared to 80.6 and 52.4 in the greater
than or equal to five organ failures group (p<0.0001 for both).
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Therapies
Statistics concerning early goal‐directed therapy and other interventions are detailed in
Table 7. Patients with a greater number of organ dysfunctions received corticosteroids (36.9%),
blood products (16.2%) and activated protein C (3.6%) more frequently than patients with fewer
organ dysfunctions (26.1%, p=0.03; 3.7%, p<0.0001; and 0.2%, p=0.008; respectively). Notably,
the overall rates of activated protein C were extremely low (n=5 or 1%). Source control, tight
glucose control and antibiotic rates were similar among both groups, as well as time to
antibiotics and rates of appropriate microbial coverage.

Table 7. Early goal‐directed therapy and other interventions
All patients
(n=521)

<5 organ
dysfunctions
(n=410)

≥5 organ
dysfunctions
(n=111)

p‐value*

469 (90.0)
2:39 ± 2:18
277 (92.9)
148 (28.4)
90 (17.3)
33 (6.3)
34 (6.5)
5 (1.0)

366 (89.3)
2:23 ± 1:41
208 (92.0)
107 (26.1)
74 (18.0)
15 (3.7)
28 (6.8)
1 (0.2)

103 (92.8)
2:44 ± 2:27
69 (95.8)
41 (36.9)
16 (14.4)
18 (16.2)
6 (5.4)
4 (3.6)

0.37
0.17
0.07
0.03
0.4
<0.0001
0.67
0.008

72 (13.8)
2.8 ± 2.1
161 (30.9)
94 (18.0)
9.2 ± 5.4
102 (19.6)
69.4 ± 13.1

48 (11.7)
2.6 ± 1.8
103 (25.1)
62 (15.1)
9.5 ± 5.6
69 (16.8)
69.6 ± 12.5

24 (21.6)
4.1 ± 2.6
59 (53.2)
32 (28.8)
8.7 ± 5.1
33 (29.7)
69.2 ± 14.3

0.01
<0.0001
<0.0001
0.001
0.5
0.004
0.88

Therapies, n (%)
Antibiotics
Time to antibiotics, mean h:m ± SD
Appropriate microbial coverage**
Corticosteroids
Source control
Blood products
Tight glucose control
Activated protein C
Early goal‐directed therapy, n (%)
Documented EGDT
Intravenous fluids, mean liters ± SD
Central line
CVP
Initial CVP, mean ± SD
ScvO2
Initial ScvO2, mean ± SD

h:m, hours:minutes; SD, standard deviation; EGDT, early goal‐directed therapy; CVP, central venous pressure;
ScvO2, central venous oxygen saturation
*Bolded p‐values are <0.05 and considered statistically significant.
**Applicable to patients in whom both antibiotics were administered in the Emergency Department and at
least one microbe with antibiotic susceptibilities was identified through cultures with susceptibilities,
variables on which the clinical evaluation of appropriate microbial coverage is based. Therefore, the total
number of cases include for this data set is 298, with 226 in the <5 organ dysfunctions group and 72 in the ≥5
organ dysfunctions group.
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Individual interventions included in the early goal‐directed therapy protocol were all
employed more frequently in the five or more failures group. Specifically, EGDT was
documented in 21.6% of the patients in the high number of organ failures group compared to
11.7% (p=0.01) in the other group. Additionally, central lines (53.2%) were placed more
frequently and CVPs (28.8%) and ScvO2s (29.7%) were drawn more often in the higher organ
injuries group versus 25.1% (p<0.0001), 15.1% (p=0.001) and 16.8% (p=0.004), respectively, in
the fewer cumulative organ injuries group, though the mean values for both CVP and ScvO2
were comparable. Finally, patients with more organ dysfunctions received a larger amount of IV
fluids, a mean of 4.1 ± 2.6 L versus 2.6 ± 1.8 L (p<0.0001).

Outcomes
Table 8 outlines data regarding disposition, length of stay, mortality, vasopressor
requirement, inotrope use, mechanical ventilation, as well as Mortality in Emergency
Department Sepsis score outcomes. Disposition locations from the Emergency Department had
extremely significant differences between both experimental groups. As such, 99 patients
(89.2%) with greater than or equal to five organ dysfunctions were admitted to acute or
subacute units (i.e. intensive care unit (ICU), stepdown unit, operating room (OR) or morgue),
while 12 (10.8%) of these patients went to regular floor bed. On the other hand, patients with
fewer than five organ dysfunctions were distributed more equitably upon admission with 186
(45.4%) going to the floor and 224 (54.6%) to an acute or subacute bed. The variation between
the two groups had p‐values <0.0001 for both floor and escalated care units.
Admission rate to the intensive care unit specifically was 83.8% in the group with more
organ failures and 48.3% in the group with fewer failures (p<0.0001), and was also significant for
differences in patients going to the morgue (two or 1.5% in the higher injury group versus zero
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in the other group, p=0.04). The stepdown unit and operating room had similar admission rates
between groups.

Table 8. Disposition and Outcomes
All patients
(n=521)

<5 organ
dysfunctions
(n=410)

≥5 organ
dysfunctions
(n=111)

p‐value*

198 (38.7)
323 (63.3)
20 (3.8)
291 (55.9)
10 (1.9)
2 (0.4)

186 (45.4)
224 (54.6)
18 (4.4)
198 (48.3)
8 (2.0)
0 (0)

12 (10.8)
99 (89.2)
2 (1.8)
93 (83.8)
2 (1.8)
2 (1.8)

<0.0001
<0.0001
0.27
<0.0001
1.0
0.04

6:36 ± 4:04
4.2 ± 6.2
11.4 ± 11.0
6.8 ± 8.0

6:35 ± 3:55
3.2 ± 5.9
10.2 ± 9.7
7.1 ± 9.8

6:42 ± 4:36
7.0 ± 6.6
15.3 ± 13.9
6.6 ± 5.5

0.78
0.02
0.07
0.17

153 (29.4)
77 (14.8)
76 (14.6)
147 (28.2)
79 (15.2)
126 (24.2)
37 (7.1)

99 (24.1)
47 (11.5)
52 (12.7)
85 (20.7)
40 (9.8)
70 (17.1)
22 (5.4)

54 (48.6)
30 (27.0)
24 (21.6)
62 (55.9)
39 (35.1)
56 (50.5)
15 (13.5)

<0.0001
<0.0001
0.02
<0.0001
<0.0001
<0.0001
0.006

Total in‐hospital mortality
Septic shock patients****
Severe sepsis****

79 (15.2)
29 (33.7)
50 (11.5)

45 (11.0)
10 (22.7)
35 (9.6)

34 (30.6)
19 (45.2)
15 (21.7)

<0.0001
0.04
0.007

In‐hospital <28 day mortality
Septic shock patients****
Severe sepsis patients****

67 (12.9)
25 (29.1)
42 (9.6)

35 (8.5)
7 (15.9)
28 (7.7)

32 (28.8)
18 (42.9)
14 (20.3)

<0.0001
0.009
0.003

11.1 ± 4.6

10.7 ± 4.5

12.5 ± 4.9

0.0002

Disposition from the ED, n (%)
Floor
Acute/subacute unit
Step down unit
Intensive care unit
Operating room
Morgue
Length of stay, mean ± SD
Emergency department, hours:mins
Intensive care unit, days**
Total hospital, days**
Ventilator, days***
Study end‐points, n (%)
Mechanical ventilation
ED
ICU/OR
Vasopressors
ED
< 72 hours
Inotropes

MEDS Score, mean ± SD

ED, emergency department; hours:mins, hours:minutes; SD, standard deviation; ICU, intensive care unit; OR,
operating room
*Bolded p‐values are <0.05 and considered statistically significant.
**Value computed from last 109 cases reviewed, as this is a new data point in the registry and has not yet
been updated for the remaining patients.
***Value computed from last 109 cases reviewed that were also mechanically ventilated (n=25), as this is a
new data point in the registry and has not yet been updated for the remaining patients.
****Severe sepsis and septic shock here refer to diagnoses in the ED based on study inclusion criteria.
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Mean emergency department and total hospital lengths of stay, as well as ventilator
days, were equivalent between both groups (note that total hospital length of stay and
ventilator days were only recorded for the last 109 patients included in the registry).
However, mean intensive care unit lengths of stay were significantly increased for the higher
organ failures group (7.0 days ± 6.6) over the lesser organ failures group (3.2 days ± 5.9; p=0.02)
(also computed based on the last 109 patients of severe sepsis registry).

Mechanical Ventilation
Figure 3 presents mechanical ventilation rates according to narrowly stratified groups of
cumulative organ failure. Seventy‐seven patients (14.8%) were mechanically ventilated in the
ED and another 76 (14.6%) in the ICU or operating room for a total of 153 patients (29.4%).
When classified according to cumulative organ dysfunction, there was a statistically significant
difference in the rates of mechanical ventilation between both experimental groups. Twenty‐
seven percent of patients in the higher cumulative organ injuries group were intubated in the
ED, while 11.5% in the fewer cumulative organ injuries group received mechanical ventilation in
the same location (p<0.0001). Intubation rates were similarly distributed in the ICU and OR,
with 21.6% of highly organ dysfunctional compared to 12.7% of minimally organ dysfunctional
patients (p=0.02).

Vasopressors and Inotropes
Figure 4 presents vasopressor and inotrope rates according to narrowly stratified groups
of cumulative organ failures. Of the 147 patients (28.2%) who received vasopressors, 79 (15.2%)
received them in the ED and a total of 126 patients (24.2%) went on to receive vasopressors at
some point within the first 72 hours of their hospitalization. Variations among the two levels of
organ failure were extremely statistically significant for all vasopressor time points.
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Figure 3. Mechanical ventilation rates by location and cumulative end‐organ dysfunction.
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Figure 4. Vasopressor and inotrope rates and cumulative end‐organ dysfunction.
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As such, 55.9% of patients with greater than or equal to five organ failures received
vasopressors at any point during the hospitalization compared to 20.7% in the other group
(p<0.0001). Of those, 50.5% in the higher dysfunctional group versus 17.1% in the lower
dysfunctional group received this form of hemodynamic support within 72 hours (p<0.0001).
The rates of inotrope use paralleled that of vasopressors, with rates equaling 13.5% of the
greater than or equal to five organ injuries patients compared to 5.4% in the other group
(p=0.006).

Mortality
Figure 5 presents mortality rates according to narrowly stratified groups of cumulative
end‐organ failure. Similarly, Figure 6 further details the relationship between specific organ
injuries and mortality. The overall in‐hospital mortality rate in this study was 15.2% (n=79).
Septic shock patients experienced a higher mortality rate of 33.7% (n=29) than patients
diagnosed with severe sepsis (11.5%, n=50). As such, there were significant variations between
in‐hospital mortality rates of the groups representing the two levels of organ dysfunction, both
at 28‐days and total hospital length of stay. Among patients with fewer than five organ failures,
8.5% died within 28 days, while 28.8% of the greater than or equal to five organ failures group
died during that same time period (p<0.0001).
A statistically significant difference also existed among disease severity subgroups, with
42.9% of the higher number for organ dysfunctions group and 15.9% of the lower number of
organ failures group having a fatal outcome among septic shock patients (p=0.009). Similarly,
20.3% of patients with severe sepsis and high cumulative organ injuries died compared to 7.7%
in the less dysfunctional group (p=0.003).
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Figure 5. Total in‐hospital mortality rate and total number of end‐organ dysfunctions.
p<0.05 when comparing high organ failure groups** to the low organ failure group*.
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Figure 6. Mortality rate and specific organ dysfunction.
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Mortality in Emergency Department Sepsis (MEDS) Score
The two experimental groups had a statistically significant difference in mean MEDS
scores. Patients with fewer than five organ failures had a mean MEDS score of 10.7 ± 4.5, as
compared to the other group with mean MEDS score of 12.5 ± 4.9 (p=0.0002). When the
experimental groups are further stratified, the MEDS scores did not trend with cumulative organ
failure (see Figure 7). One or two, three or four and seven or more end‐organ dysfunctions
groups all have the 8‐11 MEDS score as the highest frequency group (32.8%, 32.6% and 35.3%,
respectively), while a majority (33.8%) of the five or six organ failures group had MEDS scores of
12‐15. None of the differences between the two extremes of organ injuries groups (one or two
and seven or more) in the MEDS score subgroups were statistically significant.
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Figure 7. Number of end‐organ dysfunctions compared to MEDS score.

Furthermore, the highest percentage (25.8%) of patients with MEDS scores zero to
seven (0‐7) emerge within the one or two organ dysfunctions group, as the rates descend with
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increasing cumulative organ dysfunction within this MEDS score group. Likewise, the highest
percentage (26.5%) of patients with MEDS scores ≥16 fall within the greater than or equal to
seven organ failures group, with descending rates as the number of cumulative organ failures
decrease.
Finally, when comparing MEDS scores to the three study end‐points, mortality,
vasopressor and mechanical ventilation rates, no clear relationship emerged (see Figure 8).
Vasopressor rates were nearly stable across the four MEDS score groups, with 21.2%, 24.6%,
26.0% and 24.2% of patients with MEDS scores in ascending order receiving this support. On
the other hand, intubation and mortality rates peaked among the 8‐11 MEDS score group, at
41.9% and 17.4%, respectively. Otherwise, mortality rates remained steady across all groups,
while rates of mechanical ventilation decreased from the 8‐11 to the ≥16 MEDS score groups.

Mortality Rate

Early Vasopressor Rate

45.0%

Intubation Rate

41.9%

40.0%

36.3%

35.0%
30.0%

24.2%
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(n=167)

12‐15
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(n=95)

MEDS Scores

Figure 8. MEDS scores and mortality, early (<72 hour) vasopressor and mechanical ventilations rates.
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Discussion
The primary aim of this study was to determine if cumulative organ dysfunction in
patients presenting to the Emergency Department with severe sepsis and septic shock is a
predictor of mortality. Toward this goal, we found that mortality rates increased as patients
amassed more organ dysfunctions. These findings complement and enhance the existing
literature by demonstrating that cumulative organ dysfunction identified in an ED, rather than
the ICU setting, can be predictive of outcome. We also discovered that cumulative organ failure
was associated in a linear fashion with pre‐fatal indicators of deterioration, including mechanical
ventilation, vasopressor and inotrope rates.
Additionally, this is the only study to our knowledge that specifically evaluates the
relationship between organ dysfunction and mortality in patients receiving currently
recommended therapies such as EGDT, corticosteroids, vasopressors and mechanical ventilation
in an ED. Despite a higher frequency of critical interventions in patients with five or more organ
failures, mortality rates still reached approximately 56% in patients with seven or more
dysfunctions, underscoring the role of cumulative organ dysfunction as a lethal component of
severe sepsis.
Our study also contrasts the investigations of the ICU‐based MODS and SOFA score, as
well as the ED study from Shapiro and others, which demonstrated that much higher rates of
mortality prior to the advent of EDGT in septic patients. For instance, Shapiro et al. revealed the
following mortality rates: no organ dysfunction (1.0% mortality), one organ dysfunction (5.9%
mortality), two (12.5% mortality), three (25.9% mortality), and four or more (53.3% mortality),
which are substantially higher than our mortality rates of 8.7% (one or two organ failures),
13.8% (three or four organ failures), 19.5% (five or six organ failures) and 55.9% (seven or more)
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Despite the intuitive nature of the premise examined in this study, that cumulative
organ dysfunction correlates with mortality, Yale‐New Haven hospital did not have an ED sepsis
order set to monitor organ dysfunction up until approximately one and a half years ago.
Furthermore, Yale medical student Sundeep Bhat had to exclude a significant proportion
(approximately 25%) of patients from his lactate clearance thesis project using this same severe
sepsis registry because they did not have lactates drawn in the ED (113).
Presumably, there are many EDs that treat critically ill septic patients that still do not
draw comprehensive labs for the appropriate evaluation of organ injury, decreasing the
likelihood that cumulative organ dysfunction monitoring is a standard of care, as clinicians are
not likely to consciously incorporate cumulative organ failure into crucial decision‐making
without such data. Therefore, this study could help mold sepsis‐related medical practices by
encouraging the implementation of a comprehensive, ED‐based protocol to evaluate laboratory
and clinical evidence of end‐organ dysfunction.
We also discovered that cumulative organ injury was associated in a linear fashion with
pre‐fatal indicators of deterioration, including mechanical ventilation, vasopressor and inotrope
rates. Interestingly, inotrope rates for the more severe organ dysfunction group parallels that of
the original EDGT trial (13.5% versus 13.7%, respectively) which recommended the use of
dobutamine in its protocol (24). Given that these interventions are most safely employed in
acute post‐ED settings such as the ICU, these results support the role of cumulative organ
dysfunction in disposition assessments.
Interestingly, 186 (45.4%) patients with fewer than five organ failures (which had a total
in‐hospital mortality rate of 11% overall) were sent to regular medical or surgical floor beds
upon discharge from the ED. There were 11 fatalities (5.9%) among this subgroup of patients.
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While this value is lower than the overall mortality for this group of patients, it is still higher
than the Yale‐New Haven Hospital mortality rates for STEMI alerts, modified traumas and acute
stroke patients (113). Therefore, one could argue that all patients with severe sepsis or sepsis
shock, regardless of modifiers of disease severity, should be admitted to acute care units initially
from the ED.
Despite these optimistic findings relating organ dysfunction with mortality, mechanical
ventilation and vasopressor rates, neither cumulative organ injury nor mortality correlated with
the previously externally validated and deemed generalizable Mortality in Emergency
Department Sepsis (MEDS) score. This null association may be a flaw of the study design, as this
was a retrospective chart review which relied solely on documentation of clinical data that is
designed to be prospectively determined in the MEDS score. While the data in the one study
that failed to associate MEDS score with mortality were derived prospectively, it was also
applied post hoc, similar to our retrospective application of the MEDS score (83). Furthermore,
like this other study with a null finding, the poor correlation between MEDS scores and mortality
was found predominantly in the moderate ranging MEDS scores (i.e. 5‐15 MEDS score group in
the other study compared with the 8‐15 group in this study).
One such difficult parameter to assess retrospectively from limited charted information
was the determination of terminal illness. Shapiro el al. defined terminal illness as “metastatic
cancer or a disease condition with a >50% likelihood of predicted fatality within 30 days” in the
original study to derive the MEDS score (50). Given that such a determination of fatality within
30 days is heavily dependent on other details of a patient’s medical history that was not likely
outlined in the specific visit medical records used in this study, we relied on the presence of
cancer or cancer with chemotherapy as an indicator of the presence of terminal illness.
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With 21st century advancements in the treatment of cancer, the mere presence of
cancerous cells does not denote terminal illness. This simplification likely severely skewed the
MEDS score values given that terminal illness receives the greatest number of points (six) given
to any parameter in the calculation, even despite the fact that the prevalence of cancer with or
without chemotherapy had similar rates among both experimental groups. Therefore, to
evaluate the effect of this generalization, a modified MEDS (MOD MEDS) score was computed
for every patient, eliminating terminal illness as a component. The scores were then compared
to the primary study end‐point, mortality.
Figure 11 represents the association between the modified MEDS score and mortality.
As expected, there is a linear relationship between this risk stratification model and death in
patients with severe sepsis and septic shock, however, it is only statistically significant between
the lowest MOD MEDS score group (0‐7) and the other three groups (8‐11, p=0.03; 12‐15,
p=0.004; and 16 or more groups, p=0.02). Despite this, the mortality rate progression with
increasing MOD MEDS scores (MOD MEDS 0‐7, 10.0%; MOD MEDS 8‐11, 17.4%; MOD MEDS 12‐
15, 25.4%; MOD MEDS ≥16, 36.4%) is more similar to the original MEDS study mortality rates
(MEDS 0‐4, 1.1%; MEDS 5‐7, 4.4%; MEDS 8‐12, 9.3%; MEDS 12‐15, 16%; and MEDS >15, 39%, in
the validation set) than our MEDS score data including terminal illness.
It is reasonable that this ambiguity within the higher values categories in the terminal
illness correction is a result of the fact the MOD MEDS score subgrouping remains the same (i.e.
0‐7, 8‐11, 12‐15 and ≥16) as the MEDS score categories which included terminal illness in this
study, despite significant reductions in total possible points. Because of this, the two modified
MEDS score groups at the highest extremes of the population have very few numbers from
which to evaluate the relationship. Thus, the statistical relationship between the prediction
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score groups and mortality may be underestimated due to the likely suboptimal grouping of
modified MEDS score classifications.
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8‐11
(n=201)
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Modified MEDS* Scores (excluding terminal illness)

Figure 10. Modified MEDS Score (excluding terminal illness) and mortality rates.
*MOD MEDS score, Modified Mortality in Emergency Department Sepsis score.

**p=0.03 between the MOD MEDS score 0‐7 and 8‐11.
***p=0.004 between MOD MEDS score 0‐7 and 12‐15.
****p=0.02 between MOD MEDS 0‐7 and ≥16.

Another plausible cause for the failed association between mortality and the Shapiro et
al. MEDS score is that it does not include lactic acidosis or acute renal failure as derivatives.
Table 3 demonstrates that the most frequently occurring organ dysfunctions in this sample
population were elevated lactate (45.7%), acidosis (44.1%) and renal failure (39.9%). While
adding a point value for each specific organ failure to a risk stratification tool would render it
unnecessarily cumbersome and time consuming, it may be tremendously beneficial to replace
one of the current parameters (i.e. hypoxia/tachypnea, which is likely already represented by
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the presence of lower respiratory infection) with lactic acidosis, which was not evaluated in the
original study and has been demonstrated to be an independent predictor of mortality (53‐58).
While comparing the two experimental groups, some distinctions in baseline
characteristics emerged. First, there was a higher preponderance of male patients (59.5%) in
the more severely organ dysfunctional group versus female (40.5%). It stands to reason that
this difference might be attributed to either age or number of baseline co‐morbidities. As such,
the mean age of men in each group was comparable to the group mean and to each other.
However, men had a statistically significant greater number of co‐morbidities compared to
women, with means of 3.2 and 2.8, respectively (p=0.005) in the five or more organ failures
group.
Likewise, there were variations in the distribution of some key co‐morbidities. For
instance, there was actually an inverse relationship between residence in an extended care
facility and organ dysfunction, with more patients (33.4%) in the fewer than five organ injuries
group and fewer (19.8%) patients in the five or more organ injuries group. Perhaps this can be
attributed to level of surveillance patients receive in group living facilities that facilitate the early
detection of sepsis syndrome, hence earlier presentation to the ED before disease progression
to fulminate end‐organ damage. Another plausible explanation is that patients who were more
severely ill and likely to fall in the high organ dysfunction category may have had code status
documentation of comfort measures only that precluded inclusion in this study.
Liver disease and congestive heart failure (CHF) were also disproportionate among the
two groups. Perhaps liver disease as a predisposing factor was more prevalent among the five
or more organ failures group because of its relationship to many of the end‐organ injuries
measured in this study, including coagulopathy given that the liver is the site of production of
coagulation factors, hyperbilirubinemia, altered mental status through hyperammonemia,
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creatinine by way of hepato‐renal syndrome and thrombocytopenia through splenic platelet
sequestration, relatively decreased thrombopoietin synthesis and immune complex‐associated
platelet clearance (114). In like manner, CHF is also a formidable disease that complicates
treatment of sepsis syndrome by tempering a fundamental intervention, intravenous fluid.
Furthermore, it was determined to be a predictor of death in the MEDS score study and may be
associated with a sicker population overall.
Statistically significant elevations of troponin, lactate and creatinine, as well as lower
bicarbonate which is associated with renal function, in the five or more organ dysfunctions
groups is intuitive given that these are markers of the cardiac, hemodynamic and renal failures.
However, the explanation of differences in hematocrit is less obvious. One could expect the
hematocrit of the more severe organ injury group to be higher in the case of predominance of
hemoconcentration due to poorer volume status. However, the inverse was found in this study,
with the mean hematocrit being 37.2 g/dL in the fewer than five versus 35.5 g/dL in the five or
more organ failures group. This disparity may be a reflection of the larger volume of
intravenous fluids administered to the higher organ dysfunction group before labs were drawn
or be an indicator of decreased red blood cell synthesis or increased destruction in more
critically ill patients. Nevertheless, while the difference in hematocrit was statistically significant
between experimental groups, it is unlikely to be clinically significant.
The increased yield of positive blood cultures with increasing cumulative organ injury
may be an indicator of a higher bacterial load in that group, given that blood cultures were
drawn at the same rate. In like manner, the very low mean systolic blood pressure and mean
arterial pressure values for the five or more organ failures group likely corresponds with the
preponderance for septic shock patients in this group and subsequent mortality.

P a g e | 57
Finally, patterns across both groups concerning therapies and interventions reflect
expected effects. The null difference between antibiotic administration, timing and
appropriateness, as well as source control, is a reflection of the standardization of these
practices. On the contrary, less proven treatments such as corticosteroids and activated protein
C were used more often in the higher severity organ failure group given that these patients had
more indicators of poor outcomes and likely required more aggressive interventions. Finally,
the previously mentioned difference in hematocrit may account for the increased blood
products given to the five or more organ dysfunctions group.
There was poor documentation overall of the implementation of the EGDT protocol by
clinicians in this study (13.8%), though many employed multiple aspects of the protocol
independent of formal documentation. As a consequence of disease severity, clinicians were
more likely to document that they followed the protocolized form of EGDT, administering a
higher volume of intravenous fluid, while placing more central lines leading to more CVP and
ScvO2 draws, in the high organ injuries group.
However, it is curious that there were no differences in the mean initial values for CVP
and ScvO2 among the two experimental groups. This may in part be attributed to a
phenomenon known as “venous superoxia.” As disease progression in severe sepsis and septic
shock leads to greater tissue damage, oxygen extraction by the tissues plummets. This critical
consequence causes shunting of oxygen from the arterial supply to venous vasculature
triggering central venous oxygen saturation to rise as opposed to decrease as expected with
oxygen delivery‐consumption mismatch that typically occurs in the more proximal stages of the
illness.
Another major concern for clinicians treating septic patients in the Emergency
Department is appropriate disposition to hospital units based on acuity. While the patients with
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greater organ failures were more likely to go to acute units with critical monitoring and
treatment capabilities, 10.8% of potentially very ill patients went to a regular floor bed despite
having five or greater organ injuries. This disparity could potentially be reduced if cumulative
organ failure was a component of disposition algorithms.
As a consequence of more frequent ICU disposition, of the 109 patients for which this
parameter was reviewed, those with five or more organ failures had significantly increased ICU
length of stays. Interestingly, despite significant differences in mechanical ventilation rates,
there is no difference in mean ventilator days between both groups. This may reflect the fact
that a significant portion of patients are likely intubated early for non‐disease or protocol‐
related reasons such as airway protection. Furthermore, since only a small percentage of the
patients in the registry had this factor included, the numbers may not be sufficiently large
enough to power an appropriate evaluation.

Limitations
General limitations in this study arise from its retrospective methodology.
Interpretation of historical data included in medical records may differ from investigator to
investigator, as multiple investigators contributed to the severe sepsis registry. To mitigate this,
over 500 overlapping data points were collected by clinical investigators Sundeep Bhat and
Melissa Wollan with 95% precision. Similarly, standards of documenting such information on
data collection forms may vary leading to extraction error. Omitted or incorrectly or illegibly
recorded information also jeopardizes the accuracy of the data collection.
Another major limitation of the retrospective design of this study is detection bias
leading to underreporting of organ failures because the necessary laboratory tests were not
assessed in the ED, a problem that would be avoided in a prospective study following a strict
protocol. For example, only 60.8% of patients had a troponin value measured. Similarly, 78.1%
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had a bilirubin value, 84.8% lactate, 87.5% prothrombin time, 91.9% partial thromboplastin time
and 93.3% of patients had an international normalized ratio, as compared to nearly 100% of
patients with both complete blood counts and electrolyte values, including creatinine.
Furthermore, even among those laboratory data that were sent, several results returned
insufficient quantity or invalid due to hemolysis and were not repeated in the ED for evaluation
of cumulative organ injury. A similar argument can be made for other components of the study,
such as the poor documentation of EGDT and calculation of Glasgow Coma Scores, which were
derived from physical exams if not explicitly noted. Finally, differences in cultures sent could
also contribute to the biased detection of microbes and thus suboptimal evaluation of antibiotic
appropriateness.
This study is also limited by the sample population derived from a single institution.
Furthermore, patients chosen for the database were selected based on a level of awareness of
the principal investigator of their clinical condition and not a pre‐determined standardized
clinical variable, such as blood cultures drawn or antibiotic administration, a design
characteristic that may produce sample selection bias toward patients known to fit inclusion
criteria. Moreover, because multiple clinicians are not involved in the identification of potential
patients for the registry, many patients meeting inclusion criteria for the severe sepsis registry
are missed. Furthermore, patients with shorter ED lengths of stay may not have been identified,
exposing the study to lead time bias. Finally, the study data were not adjusted for confounding
variables.

Future Directions
Future research to expound upon the data presented here could include a logistic
regression model to identify which specific organ dysfunctions have higher associations with
mortality. Additionally, continued investigation of the lack of congruency between the MEDS
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score and mortality in this study is needed, particularly with regard to the potential inclusion of
lactic acidosis and the exclusion/clarification of terminal illness. Likewise, a prospective study
comparing cumulative organ dysfunction with the MEDS score as predictions tools for mortality
would likely contribute significantly toward the goal of reliable, ED‐based risk stratification of
septic patients.
Furthermore, hospital, ICU and ventilator days should be computed for the remaining
patients in the severe sepsis registry in order to extrapolate this information more accurately
and potentially complete a cost‐benefit analysis. Finally, we suspect that mortality rates at this
institution have improved significant over time and an evaluation of this trend would likely
support the continued use of currently employed treatments.

Conclusion
Despite current standards to identify and treat severe sepsis and septic shock early in
the disease progression, patients with sepsis syndrome can experience delays in care or
inappropriate treatments due to the cryptic nature of the illness’ presentation. While a
multitude of data exist upon which to risk stratify patients presenting to the Emergency
Department, there is still a critical need for a simplified, easily manipulated means to ensure
maximum treatment to reduce mortality from sepsis syndrome. Therefore, in order to arrive at
this tool, continued exploration of the key factors in predicting mortality is paramount.
This study demonstrated that the Emergency Department assessment of cumulative
organ dysfunction is a promising measurement of disease severity in patients who present to
the Emergency Department with severe sepsis and septic shock and may be implemented in
existing ED‐based risk stratification models to produce better outcomes. Cumulative organ
dysfunction could even be a superior predictor to existing and more complicated prediction
scores. Not only does cumulative organ dysfunction correlate with mortality, it is also
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associated with pre‐fatal escalations of care such as early vasopressor and mechanical
ventilation use. All of these relationships are useful for the safe and appropriate disposition of
patients from the ED in an effort to reduce sepsis‐related mortality.
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Appendix
Sex:

Male

Female

Age______________

1.

EXCLUSION CRITERIA
Age <18
Pt with documented comfort measures prior to, or during stay in ED
Sepsis (2 SIRS + Source and without organ failure)
Discharged to home

2.

SIRS (at least two of the following):
Temperature > 100.4 or < 96.8 degrees Fahrenheit
Heart Rate > 90 beats per minute
Respiratory Rate > 20 breaths per minute or PCO2 less than 32 mm Hg
White blood cell count > 12x103 or < 4x103 or > 10% immature neutrophils

3.

SOURCES (any one of the following):
WBC >10,000 or <4000 or >10% bands
Temp > 100.4 or < 96.8
Blood cultures drawn in ED
Antibiotics administered in ED
Documentation of presumed source of infection in ED‐ LOCATION:
PNA – upper or lower respiratory by physical exam or chest x‐ray
Genitourinary – by urinalysis, physical exam or diagnostic study
Intra‐abdominal – peritonitis, abscess, or other suspected source
Soft Tissue – cellulitis, necrotizing fasciitis, abscess, or ulceration of skin
Other – (Ex—CNS, line, etc.) List: ________________________

4.

END‐ORGAN DYSFUNCTION (any one of the following):
Transient systolic BP <90 that responds to fluid resuscitation
Lactate level > 2mmol/mL
Unexplained acidosis (pH < 7.35) or a serum bicarbonate < 21
Altered mental status (change from baseline)
Platelets <150,000 mm3 (no hx thrombocytopenia)
Elevation of bilirubin above normal or (direct or indirect) > than baseline
High coagulation factors (any elevation in absence of heparin or coumadin use)
Acute Renal Failure (Cr >0.5 from baseline, or abnormal if no baseline available)
Hypoxemia (oxygen saturation less than 90% or change in oxygen requirement)
Troponin elevation above baseline
Other – please list: ________________________

5.

CLASSIFICATION (Highest classification at any point in ED)
Severe Sepsis (2 SIRS + Source+ Organ Failure)
Septic Shock (SBP < 90mmHg after IVF)

6.

Inclusion in Study:
Yes – meets all inclusion criteria and does not meet any exclusion criteria
No – does NOT meet all Inclusion Criteria, or meets any Exclusion Criteria

7.

Extremis:
Pt in extremis SBP< 80 and/or started on Vasopressors <15mins of arrival to ED
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1. TIME (24:00):

_

ED Presentation: Triage VS (T0)
ED Discharge: Last RN note or VS (Tf)

__ __ : __ __

2. VITAL SIGNS (Initial to Discharge from ED or start of Vasopressor)
TIME

SBP

DBP

HR

Temp

Pox

RA, NC

N/A

N/A

Initial
Final
TIME

SBP

DBP

HR

TIME

1

9

2

10

3

11

4

12

5

13

6

14

7

15

8

16

SBP

DBP

HR

3. OTHER VITALS: (IN ED)
Lowest SBP

_________

Lowest DBP __________

Highest RR: __________ breaths/minute

Highest Temp: __________

Lowest SaO2: __________ *on: __________

4. GCS (Triage or scored from neuro exam) __________
5. FLUIDS (in ED)

TIME START __ __ : __ __

TRIAGE:_________ mL +

6. ANTIBIOTICS

ED ________ mL =

NO

YES

Vancomycin

Zosyn

Ciprofloxacin

Ceftriaxone

Gentamycin

Doxycycline

Other(s) ______________________

TOTAL __________ mL

TIME STARTED __ __: __ __
Flagyl

Unasyn
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Appropriate ED ABX Coverage

7. CULTURES/SENSITIVITIES
BLOOD

NO

RESULTS:

n/a

YES‐ TIME __ __: __ __

No Growth

URINE

____________DATE: __ __ / __ __ / __ __

NO

RESULTS:

n/a

YES‐ TIME __ __: __ __

No Growth

OTHER

____________DATE: __ __ / __ __ / __ __

NO

RESULTS:

n/a

Inappropriate

YES‐ TIME __ __: __ __

No Growth

____________DATE: __ __ / __ __ / __ __

8. PAST MEDICAL HISTORY (from ED notes or discharge Summary)
Nursing Home Residence

NO

Liver Disease

CHF ‐

COPD

Asthma

EF______

Immunocompromised (NOS)
CVA/TIA

YES
No Echo

CAD

ESRD

DM

ETOH

HIV/AIDS

Cancer

Cancer w/ chemo

Alzheimers/Dementia/MR/Chronic AMS at baseline

Other Significant ______________________________________________________
9. LABORATORY DATA (Initial)
WBC

______

Bands ______%

Hct

_____

Na

______

Cl

______

BUN

_____

K

______

HCO3

______

Cr

_____

Bt

______

Bd

______

Trop

_____

PT

______

INR

______

PTT

_____

Plt

______

Baseline Cr ______

10. LACTATE (Value/Time and Date)
1st ED____/____ ED Peak____/____
11. ABG’s – INITIAL

1st Floor ____/____ Floor Peak____/____

_____ / _____ / _____ / _____

Time __ __ : __ __

Lowest pH ______ Other PO2____________________________________

HTN
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NO

12. Early Goal Directed Therapy: Documented in Note

YES

a. Central Line Placed

NO

YES

TIME __ __: __ __

b. Initial ED CVP____ Peak ____

NO

YES

TIME __ __: __ __

c. ScvO2 (VBG) ________

NO

YES

TIME __ __: __ __

1st 24 hours ______ ______ ______ ______ ______ ______ ______
d. Vasopressors in ED
Vasopressors in Hospital
Norepinephrine

NO

YES

NO

YES

Dopamine

TIME __ __: __ __
<72h

>72h

Other______________________

e. Inotropes in ED

Dobutamine

Digoxin

Inotropes in ICU

Dobutamine

Digoxin

13. OTHER TREATMENTS:
a. Corticosteroids

NO

YES

IN ED

IN Floor

b. Source Control

NO

YES

IN ED

IN Floor

Type:

Line pulled

abscess drained

to OR

Other:_________

c. Mechanical Ventilation

NO

YES

IN ED

d. Tight Glucose Control

NO

YES

IN ED

e. Blood Products in ED

NO

YES Type ________________

f. Activated protein C (Xigris)

NO

YES

IN ED

14. DISPOSITION from ED
Admitted
Morgue
15. OUTCOME

ICU

STEP DOWN

FLOOR

OR

Other ____________
Survived hospital discharge
Died In Hospital
Died in Hospital < 28 days

IN ICU

IN ICU
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16. ED Attending DIAGNOSES
1) _______________________ 2) _____________________ 3) ____________________
17. FINAL HOSPITAL DIAGNOSES on DISCHARGE SUMMARY
1) _______________ 2) ______________ 3) ________________ 4) ________________
18. RAPID SEQUENCE INTUBATION INFORMATION (ED, floor, or OR):
Induction agent:
Etomidate

Fentanyl

Propofol

Midazolam

Ketamine

Thiopental

Other: (List) _______________________________________

No induction medications
Intubated in OR:

Yes

19. SEPSIS MIMIC

No

20. EMCCM PT

No

No

Yes

Yes

21. Patient on beta‐blocker prior to presentation:

Hospitalization Information (length of stay = LOS):
Initial ICU LOS (days):

_________

Total ICU LOS (days):

_________

Hospital LOS (days):

_________

Initial ventilator days:

_________

Total ventilator days:

_________

No

Yes

